ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE MEDICINAL PRODUCT**

Eliquis 2.5 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 2.5 mg apixaban.

**Excipients with known effect**

Each 2.5 mg film-coated tablet contains 51.43 mg lactose (see section 4.4).

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Film-coated tablet (tablet)

Yellow, round tablets debossed with 893 on one side and 2½ on the other side.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).

4.2 **Posology and method of administration**

**Posology**

*Prevention of VTE (VTEp): elective hip or knee replacement surgery*

The recommended dose of apixaban is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery.

Physicians may consider the potential benefits of earlier anticoagulation for VTE prophylaxis as well as the risks of post-surgical bleeding in deciding on the time of administration within this time window.

*In patients undergoing hip replacement surgery*

The recommended duration of treatment is 32 to 38 days.

*In patients undergoing knee replacement surgery*

The recommended duration of treatment is 10 to 14 days.

*Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)*

The recommended dose of apixaban is 5 mg taken orally twice daily.
Dose reduction
The recommended dose of apixaban is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL (133 micromole/L).

Therapy should be continued long-term.

Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEs)
The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily. As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g., recent surgery, trauma, immobilisation).

The recommended dose of apixaban for the prevention of recurrent DVT and PE is 2.5 mg taken orally twice daily. When prevention of recurrent DVT and PE is indicated, the 2.5 mg twice daily dose should be initiated following completion of 6 months of treatment with apixaban 5 mg twice daily or with another anticoagulant, as indicated in Table 1 below (see also section 5.1).

Table 1:

<table>
<thead>
<tr>
<th>Treatment of DVT or PE</th>
<th>Dosing schedule</th>
<th>Maximum daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10 mg twice daily for the first 7 days</td>
<td>20 mg</td>
</tr>
<tr>
<td></td>
<td>followed by 5 mg twice daily</td>
<td>10 mg</td>
</tr>
</tbody>
</table>

The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).

Missed dose
If a dose is missed, the patient should take Eliquis immediately and then continue with twice daily intake as before.

Switching
Switching treatment from parenteral anticoagulants to Eliquis (and vice versa) can be done at the next scheduled dose (see section 4.5). These medicinal products should not be administered simultaneously.

Switching from vitamin K antagonist (VKA) therapy to Eliquis
When converting patients from vitamin K antagonist (VKA) therapy to Eliquis, warfarin or other VKA therapy should be discontinued and Eliquis started when the international normalised ratio (INR) is < 2.

Switching from Eliquis to VKA therapy
When converting patients from Eliquis to VKA therapy, administration of Eliquis should be continued for at least 2 days after beginning VKA therapy. After 2 days of coadministration of Eliquis with VKA therapy, an INR should be obtained prior to the next scheduled dose of Eliquis. Coadministration of Eliquis and VKA therapy should be continued until the INR is ≥ 2.
Renal impairment
In patients with mild or moderate renal impairment, the following recommendations apply:

- for the prevention of VTE in elective hip or knee replacement surgery (VTEp), for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), no dose adjustment is necessary (see section 5.2).

- for the prevention of stroke and systemic embolism in patients with NVAF and serum creatinine ≥ 1.5 mg/dL (133 micromole/L) associated with age ≥ 80 years or body weight ≤ 60 kg, a dose reduction is necessary and described above. In the absence of other criteria for dose reduction (age, body weight), no dose adjustment is necessary (see section 5.2).

In patients with severe renal impairment (creatinine clearance 15-29 mL/min) the following recommendations apply (see sections 4.4 and 5.2):

- for the prevention of VTE in elective hip or knee replacement surgery (VTEp), for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) apixaban is to be used with caution;

- for the prevention of stroke and systemic embolism in patients with NVAF, patients should receive the lower dose of apixaban 2.5 mg twice daily.

In patients with creatinine clearance < 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.4 and 5.2).

Hepatic impairment
Eliquis is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).

It is not recommended in patients with severe hepatic impairment (see sections 4.4 and 5.2).

It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B). No dose adjustment is required in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).

Patients with elevated liver enzymes alanine aminotransferase (ALT)/aspartate aminotransferase (AST) >2 x ULN or total bilirubin ≥ 1.5 x ULN were excluded in clinical trials. Therefore Eliquis should be used with caution in this population (see sections 4.4 and 5.2). Prior to initiating Eliquis, liver function testing should be performed.

Body weight
VTEp and VTEt - No dose adjustment required (see sections 4.4 and 5.2).

NVAF - No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2).

Gender
No dose adjustment required (see section 5.2).

Elderly
VTEp and VTEt – No dose adjustment required (see sections 4.4 and 5.2).

NVAF – No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2).

Patients undergoing cardioversion
Apixaban can be initiated or continued in NVAF patients who may require cardioversion.
For patients not previously treated with anticoagulants, at least 5 doses of apixaban 5 mg twice daily (2.5 mg twice daily in patients who qualify for a dose reduction (see above sections Dose reduction and Renal impairment)) should be given before cardioversion to ensure adequate anticoagulation (see section 5.1).

If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily. The dosing regimen should be reduced to a 5 mg loading dose followed by 2.5 mg twice daily if the patient meets the criteria for dose reduction (see above sections Dose reduction and Renal impairment). The administration of the loading dose should be given at least 2 hours before cardioversion (see section 5.1).

Confirmation should be sought prior to cardioversion that the patient has taken apixaban as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.

**Paediatric population**
The safety and efficacy of Eliquis in children and adolescents below age 18 have not been established. No data are available.

**Method of administration**

Oral use
Eliquis should be swallowed with water, with or without food.

For patients who are unable to swallow whole tablets, Eliquis tablets may be crushed and suspended in water, or 5% dextrose in water (D5W), or apple juice or mixed with apple puree and immediately administered orally (see section 5.2). Alternatively, Eliquis tablets may be crushed and suspended in 60 mL of water or D5W and immediately delivered through a nasogastric tube (see section 5.2). Crushed Eliquis tablets are stable in water, D5W, apple juice, and apple puree for up to 4 hours.

### 4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Active clinically significant bleeding.
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 5.2).
- Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
- Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

### 4.4 Special warnings and precautions for use

**Haemorrhage risk**
As with other anticoagulants, patients taking Eliquis are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Eliquis administration should be discontinued if severe haemorrhage occurs (see sections 4.8 and 4.9).
Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see section 5.1).

**Interaction with other medicinal products affecting haemostasis**
Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).

The concomitant use of Eliquis with antiplatelet agents increases the risk of bleeding (see section 4.5).

Care is to be taken if patients are treated concomitantly with non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid.

Following surgery, other platelet aggregation inhibitors are not recommended concomitantly with Eliquis (see section 4.5).

In patients with atrial fibrillation and conditions that warrant mono or dual antiplatelet therapy, a careful assessment of the potential benefits against the potential risks should be made before combining this therapy with Eliquis.

In a clinical trial of patients with atrial fibrillation, concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on warfarin from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.1%) use of concomitant dual antiplatelet therapy.

In a clinical trial of high-risk post acute coronary syndrome patients, characterised by multiple cardiac and non-cardiac comorbidities, who received ASA or the combination of ASA and clopidogrel, a significant increase in risk of ISTH (International Society on Thrombosis and Haemostasis) major bleeding was reported for apixaban (5.13% per year) compared to placebo (2.04% per year).

**Use of thrombolytic agents for the treatment of acute ischemic stroke**
There is very limited experience with the use of thrombolytic agents for the treatment of acute ischemic stroke in patients administered apixaban.

**Patients with prosthetic heart valves**
Safety and efficacy of Eliquis have not been studied in patients with prosthetic heart valves, with or without atrial fibrillation. Therefore, the use of Eliquis is not recommended in this setting.

**Surgery and invasive procedures**
Eliquis should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding. This includes interventions for which the probability of clinically significant bleeding cannot be excluded or for which the risk of bleeding would be unacceptable.

Eliquis should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding. This includes interventions for which any bleeding that occurs is expected to be minimal, non-critical in its location or easily controlled.

If surgery or invasive procedures cannot be delayed, appropriate caution should be exercised, taking into consideration an increased risk of bleeding. This risk of bleeding should be weighed against the urgency of intervention.

Eliquis should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established (for cardioversion see section 4.2).
Temporary discontinuation
Discontinuing anticoagulants, including Eliquis, for active bleeding, elective surgery, or invasive procedures places patients at an increased risk of thrombosis. Lapses in therapy should be avoided and if anticoagulation with Eliquis must be temporarily discontinued for any reason, therapy should be restarted as soon as possible.

Spinal/epidural anaesthesia or puncture
When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. Indwelling epidural or intrathecal catheters must be removed at least 5 hours prior to the first dose of Eliquis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g., numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.

There is no clinical experience with the use of apixaban with indwelling intrathecal or epidural catheters. In case there is such need and based on the general PK characteristics of apixaban, a time interval of 20-30 hours (i.e., 2 x half-life) between the last dose of apixaban and catheter withdrawal should elapse, and at least one dose should be omitted before catheter withdrawal. The next dose of apixaban may be given at least 5 hours after catheter removal. As with all new anticoagulant medicinal products, experience with neuraxial blockade is limited and extreme caution is therefore recommended when using apixaban in the presence of neuraxial blockade.

Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy
Eliquis is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of apixaban have not been established in these clinical situations.

Patients with active cancer
Efficacy and safety of apixaban in the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) in patients with active cancer have not been established.

Patients with renal impairment
Limited clinical data indicate that apixaban plasma concentrations are increased in patients with severe renal impairment (creatinine clearance 15-29 mL/min) which may lead to an increased bleeding risk. For the prevention of VTE in elective hip or knee replacement surgery (VTEp), the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), apixaban is to be used with caution in patients with severe renal impairment (creatinine clearance 15-29 mL/min) (see sections 4.2 and 5.2).

For the prevention of stroke and systemic embolism in patients with NVAF, patients with severe renal impairment (creatinine clearance 15-29 mL/min), and patients with serum creatinine ≥ 1.5 mg/dL (133 micromole/L) associated with age ≥ 80 years or body weight ≤ 60 kg should receive the lower dose of apixaban 2.5 mg twice daily (see section 4.2).

In patients with creatinine clearance < 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.2 and 5.2).

Elderly patients
Increasing age may increase haemorrhagic risk (see section 5.2).
Also, the coadministration of Eliquis with ASA in elderly patients should be used cautiously because of a potentially higher bleeding risk.

Body weight
Low body weight (< 60 kg) may increase haemorrhagic risk (see section 5.2).

Patients with hepatic impairment
Eliquis is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).

It is not recommended in patients with severe hepatic impairment (see section 5.2).

It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B) (see sections 4.2 and 5.2).

Patients with elevated liver enzymes ALT/AST > 2 x ULN or total bilirubin ≥ 1.5 x ULN were excluded in clinical trials. Therefore Eliquis should be used cautiously in this population (see section 5.2). Prior to initiating Eliquis, liver function testing should be performed.

Interaction with inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp)
The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir). These medicinal products may increase apixaban exposure by 2-fold (see section 4.5), or greater in the presence of additional factors that increase apixaban exposure (e.g., severe renal impairment).

Interaction with inducers of both CYP3A4 and P-gp
The concomitant use of Eliquis with strong CYP3A4 and P-gp inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital or St. John’s Wort) may lead to a ~50% reduction in apixaban exposure. In a clinical study in atrial fibrillation patients, diminished efficacy and a higher risk of bleeding were observed with coadministration of apixaban with strong inducers of both CYP3A4 and P-gp compared with using apixaban alone.

In patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp the following recommendations apply (see section 4.5):

- for the prevention of VTE in elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE, apixaban should be used with caution;

- for the treatment of DVT and treatment of PE, apixaban should not be used since efficacy may be compromised.

Hip fracture surgery
Apixaban has not been studied in clinical trials in patients undergoing hip fracture surgery to evaluate efficacy and safety in these patients. Therefore, it is not recommended in these patients.

Laboratory parameters
Clotting tests [e.g., prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT)] are affected as expected by the mechanism of action of apixaban. Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability (see section 5.1).

Information about excipients
Eliquis contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
4.5 Interaction with other medicinal products and other forms of interaction

Inhibitors of CYP3A4 and P-gp
Coadministration of apixaban with ketoconazole (400 mg once a day), a strong inhibitor of both CYP3A4 and P-gp, led to a 2-fold increase in mean apixaban AUC and a 1.6-fold increase in mean apixaban $C_{max}$.

The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see section 4.4).

Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (eg., diltiazem, naproxen, clarithromycin, amiodarone, verapamil, quinidine) are expected to increase apixaban plasma concentration to a lesser extent. No dose adjustment for apixaban is required when coadministered with agents that are not strong inhibitors of both CYP3A4 and P-gp. For example, diltiazem (360 mg once a day), considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean apixaban AUC and a 1.3-fold increase in $C_{max}$. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and $C_{max}$, respectively. Clarithromycin (500 mg, twice a day), an inhibitor of P-gp and a strong inhibitor of CYP3A4, led to a 1.6-fold and 1.3-fold increase in mean apixaban AUC and $C_{max}$ respectively.

Inducers of CYP3A4 and P-gp
Coadministration of apixaban with rifampicin, a strong inducer of both CYP3A4 and P-gp, led to an approximate 54% and 42% decrease in mean apixaban AUC and $C_{max}$, respectively. The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers (e.g., phenytoin, carbamazepine, phenobarbital or St. John’s Wort) may also lead to reduced apixaban plasma concentrations. No dose adjustment for apixaban is required during concomitant therapy with such medicinal products, however in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp apixaban should be used with caution for the prevention of VTE in elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE.

Apixaban is not recommended for the treatment of DVT and PE in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp since efficacy may be compromised (see section 4.4).

Anticoagulants, platelet aggregation inhibitors and NSAIDs
Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).

After combined administration of enoxaparin (40 mg single dose) with apixaban (5 mg single dose), an additive effect on anti-Factor Xa activity was observed.

Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325 mg once a day.

Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel 75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.

Naproxen (500 mg), an inhibitor of P-gp, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and $C_{max}$ respectively. Corresponding increases in clotting tests were observed for apixaban. No changes were observed in the effect of naproxen on arachidonic acid-induced platelet aggregation and
no clinically relevant prolongation of bleeding time was observed after concomitant administration of apixaban and naproxen.

Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplatelet agents are coadministered with apixaban. Eliquis should be used with caution when coadministered with NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk. A significant increase in bleeding risk was reported with the triple combination of apixaban, ASA and clopidogrel in a clinical study in patients with acute coronary syndrome (see section 4.4).

Medicinal products associated with serious bleeding are not recommended concomitantly with Eliquis, such as: thrombolytic agents, GPIIb/IIIa receptor antagonists, thienopyridines (e.g., clopidogrel), dipyridamole, dextran and sulfinpyrazone.

**Other concomitant therapies**

No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coadministered with atenolol or famotidine. Coadministration of apixaban 10 mg with atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban. Following administration of the two medicinal products together, mean apixaban AUC and Cmax were 15% and 18% lower than when administered alone. The administration of apixaban 10 mg with famotidine 40 mg had no effect on apixaban AUC or Cmax.

**Effect of apixaban on other medicinal products**

*In vitro* apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 µM) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 µM) at concentrations that are significantly greater than peak plasma concentrations observed in patients. Apixaban did not induce CYP1A2, CYP2B6, CYP3A4/5 at a concentration up to 20 µM. Therefore, apixaban is not expected to alter the metabolic clearance of coadministered medicinal products that are metabolised by these enzymes. Apixaban is not a significant inhibitor of P-gp.

In studies conducted in healthy subjects, as described below, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, or atenolol.

**Digoxin**

Coadministration of apixaban (20 mg once a day) and digoxin (0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or Cmax. Therefore, apixaban does not inhibit P-gp mediated substrate transport.

**Naproxen**

Coadministration of single doses of apixaban (10 mg) and naproxen (500 mg), a commonly used NSAID, did not have any effect on the naproxen AUC or Cmax.

**Atenolol**

Coadministration of a single dose of apixaban (10 mg) and atenolol (100 mg), a common beta-blocker, did not alter the pharmacokinetics of atenolol.

**Activated charcoal**

Administration of activated charcoal reduces apixaban exposure (see section 4.9).

### 4.6 Fertility, pregnancy and lactation

**Pregnancy**

There are no data from the use of apixaban in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Apixaban is not recommended during pregnancy.
Breast-feeding
It is unknown whether apixaban or its metabolites are excreted in human milk. Available data in animals have shown excretion of apixaban in milk. In rat milk, a high milk to maternal plasma ratio (C<sub>max</sub> about 8, AUC about 30) was found, possibly due to active transport into the milk. A risk to newborns and infants cannot be excluded.

A decision must be made to either discontinue breast-feeding or to discontinue/abstain from apixaban therapy.

Fertility
Studies in animals dosed with apixaban have shown no effect on fertility (see section 5.3).

4.7 Effects on ability to drive and use machines
Eliquis has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile
The safety of apixaban has been investigated in 7 Phase III clinical studies including more than 21,000 patients: more than 5,000 patients in VTEp studies, more than 11,000 patients in NVAF studies and more than 4,000 patients in the VTE treatment (VTEt) studies, for an average total exposure of 20 days, 1.7 years and 221 days respectively (see section 5.1).

Common adverse reactions were haemorrhage, contusion, epistaxis, and haematoma (see Table 2 for adverse reaction profile and frequencies by indication).

In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced adverse reactions. The overall incidence of adverse reactions related to bleeding with apixaban was 10% in the apixaban vs enoxaparin studies.

In the NVAF studies, the overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in the apixaban vs warfarin study and 9.6% in the apixaban vs acetylsalicylic acid study. In the apixaban vs warfarin study the incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) with apixaban was 0.76%/year. The incidence of ISTH major intraocular bleeding with apixaban was 0.18%/year.

In the VTEt studies, the overall incidence of adverse reactions related to bleeding with apixaban was 15.6% in the apixaban vs enoxaparin/warfarin study and 13.3% in the apixaban vs placebo study (see section 5.1).

Tabulated list of adverse reactions
Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data) for VTEp, NVAF, and VTEt respectively.

Table 2

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery (VTEp)</th>
<th>Prevention of stroke and systemic embolism in adult patients with NVAF, with one or more risk factors (NVAF)</th>
<th>Treatment of DVT and PE, and prevention of recurrent DVT and PE (VTEt)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery (VTEp)</th>
<th>Prevention of stroke and systemic embolism in adult patients with NVAF, with one or more risk factors (NVAF)</th>
<th>Treatment of DVT and PE, and prevention of recurrent DVT and PE (VTEt)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaemia</td>
<td>Common</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>Uncommon</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity, allergic oedema and Anaphylaxis</td>
<td>Rare</td>
<td>Uncommon</td>
<td>-</td>
</tr>
<tr>
<td>Pruritus</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Uncommon*</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain haemorrhage</td>
<td>-</td>
<td>Uncommon</td>
<td>Rare</td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye haemorrhage (including conjunctival haemorrhage)</td>
<td>Rare</td>
<td>Common</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemorrhage, haematoma</td>
<td>Common</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Hypotension (including procedural hypotension)</td>
<td>Uncommon</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Intra-abdominal haemorrhage</td>
<td>-</td>
<td>Uncommon</td>
<td>-</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis</td>
<td>Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Haemoptysis</td>
<td>Rare</td>
<td>Uncommon</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Respiratory tract haemorrhage</td>
<td>-</td>
<td>Rare</td>
<td>Rare</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>Common</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gastrointestinal haemorrhage</td>
<td>Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Haemorrhoidal haemorrhage, mouth haemorrhage</td>
<td>-</td>
<td>Uncommon</td>
<td>-</td>
</tr>
<tr>
<td>Haematochezia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Rectal haemorrhage, gingival bleeding</td>
<td>Rare</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Retroperitoneal haemorrhage</td>
<td>-</td>
<td>Rare</td>
<td>-</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transaminases increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, blood alkaline phosphatase increased, blood bilirubin increased</td>
<td>Uncommon</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin rash</td>
<td>-</td>
<td>Uncommon</td>
<td>-</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle haemorrhage</td>
<td>Rare</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematuria</td>
<td>Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
System Organ Class | Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery (VTEp) | Prevention of stroke and systemic embolism in adult patients with NVAF, with one or more risk factors (NVAF) | Treatment of DVT and PE, and prevention of recurrent DVT and PE (VTEt)

| Abnormal vaginal haemorrhage, urogenital haemorrhage | - | Uncommon | Uncommon

General disorders and administration site conditions

| Application site bleeding | - | Uncommon | -

Investigations

| Occult blood positive | - | Uncommon | Uncommon

Injury, poisoning and procedural complications

| Contusion | Common | Common | Common

| Post procedural haemorrhage (including post procedural haematoma, wound haemorrhage, vessel puncture site haematoma and catheter site haemorrhage), wound secretion, incision site haemorrhage (including incision site haematoma), operative haemorrhage | Uncommon | - | -

| Traumatic haemorrhage, post procedural haemorrhage, incision site haemorrhage | - | Uncommon | Uncommon

* There were no occurrences of generalized pruritus in CV185057 (long term prevention of VTE).

The use of Eliquis may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may result in posthaemorrhagic anaemia. The signs, symptoms, and severity will vary according to the location and degree or extent of the bleeding (see sections 4.4 and 5.1).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

There is no antidote to Eliquis. Overdose of apixaban may result in a higher risk of bleeding. In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. The initiation of appropriate treatment, e.g., surgical haemostasis or the transfusion of fresh frozen plasma should be considered.

In controlled clinical trials, orally-administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily (bid) for 7 days or 50 mg once daily (od) for 3 days) had no clinically relevant adverse effects.

In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20 mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively, and had no impact on C_{max}. Mean half-life of apixaban decreased from 13.4 hours when apixaban was administered alone to 5.3 hours and 4.9 hours, respectively, when activated charcoal was administered 2 and 6 hours after...
apixaban. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.

If life-threatening bleeding cannot be controlled by the above measures, administration of prothrombin complex concentrates (PCCs) or recombinant factor VIIa may be considered. Reversal of Eliquis pharmacodynamic effects, as demonstrated by changes in the thrombin generation assay, was evident at the end of infusion and reached baseline values within 4 hours after the start of a 4-factor PCC 30 minute infusion in healthy subjects. However, there is no clinical experience with the use of 4-factor PCC products to reverse bleeding in individuals who have received Eliquis. Currently there is no experience with the use of recombinant factor VIIa in individuals receiving apixaban. Re-dosing of recombinant factor VIIa could be considered and titrated depending on improvement of bleeding.

Depending on local availability, a consultation of a coagulation expert should be considered in case of major bleedings.

Haemodialysis decreased apixaban AUC by 14% in subjects with end-stage renal disease (ESRD), when a single dose of apixaban 5 mg was administered orally. Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF02

Mechanism of action
Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development. Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved haemostasis.

Pharmacodynamic effects
The pharmacodynamic effects of apixaban are reflective of the mechanism of action (FXa inhibition). As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability. They are not recommended to assess the pharmacodynamic effects of apixaban. In the thrombin generation assay, apixaban reduced endogenous thrombin potential, a measure of thrombin generation in human plasma.

Apixaban also demonstrates anti-FXa activity as evident by reduction in Factor Xa enzyme activity in multiple commercial anti-FXa kits, however results differ across kits. Data from clinical trials are only available for the Rotachrom® Heparin chromogenic assay. Anti-FXa activity exhibits a close direct linear relationship with apixaban plasma concentration, reaching maximum values at the time of apixaban peak plasma concentrations. The relationship between apixaban plasma concentration and anti-FXa activity is approximately linear over a wide dose range of apixaban.

Table 3 below shows the predicted steady state exposure and anti-Factor Xa activity for each indication. In patients taking apixaban for the prevention of VTE following hip or knee replacement surgery, the results demonstrate a less than 1.6-fold fluctuation in peak-to-trough levels. In non-valvular atrial fibrillation patients taking apixaban for the prevention of stroke and systemic embolism, the results demonstrate a less than 1.7-fold fluctuation in peak-to-trough levels. In patients taking apixaban for the treatment of DVT and PE or prevention of recurrent DVT and PE, the results demonstrate a less than 2.2-fold fluctuation in peak-to-trough levels.
Table 3: Predicted Apixaban Steady-state Exposure and Anti-Xa Activity

<table>
<thead>
<tr>
<th></th>
<th>Apix. C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</th>
<th>Apix. C&lt;sub&gt;min&lt;/sub&gt; (ng/mL)</th>
<th>Apix. Anti-Xa Activity Max (IU/mL)</th>
<th>Apix. Anti-Xa Activity Min (IU/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevention of VTE: elective hip or knee replacement surgery</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5 mg twice daily</td>
<td>77 [41, 146]</td>
<td>51 [23, 109]</td>
<td>1.3 [0.67, 2.4]</td>
<td>0.84 [0.37, 1.8]</td>
</tr>
<tr>
<td><strong>Prevention of stroke and systemic embolism: NVAF</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5 mg twice daily*</td>
<td>123 [69, 221]</td>
<td>79 [34, 162]</td>
<td>1.8 [1.0, 3.3]</td>
<td>1.2 [0.51, 2.4]</td>
</tr>
<tr>
<td>5 mg twice daily</td>
<td>171 [91, 321]</td>
<td>103 [41, 230]</td>
<td>2.6 [1.4, 4.8]</td>
<td>1.5 [0.61, 3.4]</td>
</tr>
<tr>
<td><strong>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5 mg twice daily</td>
<td>67 [30, 153]</td>
<td>32 [11, 90]</td>
<td>1.0 [0.46, 2.5]</td>
<td>0.49 [0.17, 1.4]</td>
</tr>
<tr>
<td>5 mg twice daily</td>
<td>132 [59, 302]</td>
<td>63 [22, 177]</td>
<td>2.1 [0.91, 5.2]</td>
<td>1.0 [0.33, 2.9]</td>
</tr>
<tr>
<td>10 mg twice daily</td>
<td>251 [111, 572]</td>
<td>120 [41, 335]</td>
<td>4.2 [1.8, 10.8]</td>
<td>1.9 [0.64, 5.8]</td>
</tr>
</tbody>
</table>

* Dose adjusted population based on 2 of 3 dose reduction criteria in the ARISTOTLE study.

Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery.

Clinical efficacy and safety

**Prevention of VTE (VTEp): elective hip or knee replacement surgery**

The apixaban clinical program was designed to demonstrate the efficacy and safety of apixaban for the prevention of VTE in a broad range of adult patients undergoing elective hip or knee replacement. A total of 8,464 patients were randomised in two pivotal, double-blind, multi-national studies, comparing apixaban 2.5 mg given orally twice daily (4,236 patients) or enoxaparin 40 mg once daily (4,228 patients). Included in this total were 1,262 patients (618 in the apixaban group) of age 75 or older, 1,004 patients (499 in the apixaban group) with low body weight (≤ 60 kg), 1,495 patients (743 in the apixaban group) with BMI ≥ 33 kg/m², and 415 patients (203 in the apixaban group) with moderate renal impairment.

The ADVANCE-3 study included 5,407 patients undergoing elective hip replacement, and the ADVANCE-2 study included 3,057 patients undergoing elective knee replacement. Subjects received either apixaban 2.5 mg given orally twice daily (po bid) or enoxaparin 40 mg administered subcutaneously once daily (sc od). The first dose of apixaban was given 12 to 24 hours post-surgery, whereas enoxaparin was started 9 to 15 hours prior to surgery. Both apixaban and enoxaparin were given for 32-38 days in the ADVANCE-3 study and for 10-14 days in the ADVANCE-2 study.

Based on patient medical history in the studied population of ADVANCE-3 and ADVANCE-2 (8,464 patients), 46% had hypertension, 10% had hyperlipidemia, 9% had diabetes, and 8% had coronary artery disease.

Apixaban demonstrated a statistically superior reduction in the primary endpoint, a composite of all VTE/all cause death, and in the Major VTE endpoint, a composite of proximal DVT, non-fatal PE, and VTE-related death, compared to enoxaparin in both elective hip or knee replacement surgery (see Table 4).
### Table 4: Efficacy Results from Pivotal Phase III Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>ADVANCE-3 (hip)</th>
<th>ADVANCE-2 (knee)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study treatment</td>
<td>Apixaban 2.5 mg po twice daily 35 ± 3 d</td>
<td>Enoxaparin 40 mg sc once daily 35 ± 3 d</td>
</tr>
<tr>
<td>Dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of events/subjects</td>
<td>27/1,949 1.39%</td>
<td>74/1,917 3.86%</td>
</tr>
<tr>
<td>Event Rate</td>
<td>0.36</td>
<td>0.62</td>
</tr>
<tr>
<td>Relative Risk</td>
<td>(0.22, 0.54)</td>
<td>(0.51, 0.74)</td>
</tr>
<tr>
<td>Major VTE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of events/subjects</td>
<td>10/2,199 0.45%</td>
<td>25/2,195 1.14%</td>
</tr>
<tr>
<td>Event Rate</td>
<td>0.40</td>
<td>0.50</td>
</tr>
<tr>
<td>Relative Risk</td>
<td>(0.15, 0.80)</td>
<td>(0.26, 0.97)</td>
</tr>
</tbody>
</table>

The safety endpoints of major bleeding, the composite of major and clinically relevant non-major (CRNM) bleeding, and all bleeding showed similar rates for patients treated with apixaban 2.5 mg compared with enoxaparin 40 mg (see Table 5). All the bleeding criteria included surgical site bleeding.

### Table 5: Bleeding Results from Pivotal Phase III Studies*

<table>
<thead>
<tr>
<th>Study</th>
<th>ADVANCE-3</th>
<th>ADVANCE-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apixaban</td>
<td>Enoxaparin</td>
<td>Apixaban</td>
</tr>
<tr>
<td>2.5 mg po twice daily 35 ± 3 d</td>
<td>40 mg sc once daily 35 ± 3 d</td>
<td>2.5 mg po twice daily 12 ± 2 d</td>
</tr>
<tr>
<td>All treated</td>
<td>n = 2,673</td>
<td>n = 2,659</td>
</tr>
</tbody>
</table>

**Treatment Period**

<table>
<thead>
<tr>
<th></th>
<th>ADVANCE-3</th>
<th>ADVANCE-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major</td>
<td>22 (0.8%)</td>
<td>18 (0.7%)</td>
</tr>
<tr>
<td>Fatal</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Major + CRNM</td>
<td>129 (4.8%)</td>
<td>134 (5.0%)</td>
</tr>
<tr>
<td>All</td>
<td>313 (11.7%)</td>
<td>334 (12.6%)</td>
</tr>
</tbody>
</table>

**Post-surgery treatment period**

<table>
<thead>
<tr>
<th></th>
<th>ADVANCE-3</th>
<th>ADVANCE-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major</td>
<td>9 (0.3%)</td>
<td>11 (0.4%)</td>
</tr>
<tr>
<td>Fatal</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Major + CRNM</td>
<td>96 (3.6%)</td>
<td>115 (4.3%)</td>
</tr>
<tr>
<td>All</td>
<td>261 (9.8%)</td>
<td>293 (11.0%)</td>
</tr>
</tbody>
</table>

*All the bleeding criteria included surgical site bleeding

1 Includes events occurring after first dose of enoxaparin (pre-surgery)

2 Includes events occurring after first dose of apixaban (post-surgery)

The overall incidences of adverse reactions of bleeding, anaemia and abnormalities of transaminases (e.g., ALT levels) were numerically lower in patients on apixaban compared to enoxaparin in the phase II and phase III studies in elective hip and knee replacement surgery.

In the knee replacement surgery study during the intended treatment period, in the apixaban arm 4 cases of PE were diagnosed against no cases in the enoxaparin arm. No explanation can be given to this higher number of PE.
**Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)**

A total of 23,799 patients were randomised in the clinical program (ARISTOTLE: apixaban versus warfarin, AVERROES: apixaban versus ASA) including 11,927 randomised to apixaban. The program was designed to demonstrate the efficacy and safety of apixaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and one or more additional risk factors, such as:

- prior stroke or transient ischaemic attack (TIA)
- age ≥ 75 years
- hypertension
- diabetes mellitus
- symptomatic heart failure (NYHA Class ≥ II)

**ARISTOTLE STUDY**

In the ARISTOTLE study a total of 18,201 patients were randomised to double-blind treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [4.7%], see section 4.2) or warfarin (target INR range 2.0-3.0), patients were exposed to study drug for a mean of 20 months. The mean age was 69.1 years, the mean CHADS2 score was 2.1 and 18.9% of patients had prior stroke or TIA.

In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic or ischaemic) and systemic embolism (see Table 6) compared with warfarin.

Table 6: Efficacy Outcomes in Patients with Atrial Fibrillation in the ARISTOTLE Study

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Apixaban</th>
<th>Warfarin</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=9,120 n (%/yr)</td>
<td>N=9,081 n (%/yr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke or systemic embolism</td>
<td>212 (1.27)</td>
<td>265 (1.60)</td>
<td>0.79 (0.66, 0.95)</td>
<td>0.0114</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischaemic or unspecified</td>
<td>162 (0.97)</td>
<td>175 (1.05)</td>
<td>0.92 (0.74, 1.13)</td>
<td></td>
</tr>
<tr>
<td>Haemorrhagic</td>
<td>40 (0.24)</td>
<td>78 (0.47)</td>
<td>0.51 (0.35, 0.75)</td>
<td></td>
</tr>
<tr>
<td>Systemic embolism</td>
<td>15 (0.09)</td>
<td>17 (0.10)</td>
<td>0.87 (0.44, 1.75)</td>
<td></td>
</tr>
</tbody>
</table>

For patients randomised to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%.

Apixaban showed a reduction of stroke and systemic embolism compared to warfarin across the different levels of center TTR; within the highest quartile of TTR according to center, the hazard ratio for apixaban vs warfarin was 0.73 (95% CI, 0.38, 1.40).

Key secondary endpoints of major bleeding and all cause death were tested in a pre-specified hierarchical testing strategy to control the overall type 1 error in the trial. Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 7). With improving monitoring of INR the observed benefits of apixaban compared to warfarin regarding all cause death diminish.
Table 7: Secondary Endpoints in Patients with Atrial Fibrillation in the ARISTOTLE Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban N = 9,088 n (%/year)</th>
<th>Warfarin N = 9,052 n (%/year)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bleeding Outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major*</td>
<td>327 (2.13)</td>
<td>462 (3.09)</td>
<td>0.69 (0.60, 0.80)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Fatal</td>
<td>10 (0.06)</td>
<td>37 (0.24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracranial</td>
<td>52 (0.33)</td>
<td>122 (0.80)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major + CRNM</td>
<td>613 (4.07)</td>
<td>877 (6.01)</td>
<td>0.68 (0.61, 0.75)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>All</td>
<td>2356 (18.1)</td>
<td>3060 (25.8)</td>
<td>0.71 (0.68, 0.75)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td><strong>Other Endpoints</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause death</td>
<td>603 (3.52)</td>
<td>669 (3.94)</td>
<td>0.89 (0.80, 1.00)</td>
<td>0.0465</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>90 (0.53)</td>
<td>102 (0.61)</td>
<td>0.88 (0.66, 1.17)</td>
<td></td>
</tr>
</tbody>
</table>

* Major bleeding defined per International Society on Thrombosis and Haemostasis (ISTH) criteria.

The overall discontinuation rate due to adverse reactions was 1.8% for apixaban and 2.6% for warfarin in the ARISTOTLE study.

The efficacy results for prespecified subgroups, including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the primary efficacy results for the overall population studied in the trial.

The incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) was 0.76%/year with apixaban and 0.86%/year with warfarin.

The major bleeding results for prespecified subgroups including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the results for the overall population studied in the trial.

**AVERROES STUDY**

In the AVERROES study a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomised to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%], see section 4.2) or ASA. ASA was given at a once daily dose of 81 mg (64%), 162 (26.9%), 243 (2.1%), or 324 mg (6.6%) at the discretion of the investigator. Patients were exposed to study drug for a mean of 14 months. The mean age was 69.9 years, the mean CHADS2 score was 2.0 and 13.6% of patients had prior stroke or TIA.

Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medicinal product instruction (15.0%), and difficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%).

AVERROES was stopped early based on a recommendation by the independent Data Monitoring Committee due to clear evidence of reduction of stroke and systemic embolism with an acceptable safety profile.

The overall discontinuation rate due to adverse reactions was 1.5% for apixaban and 1.3% for ASA in the AVERROES study.

In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 8) compared to ASA.
Table 8: Key Efficacy Outcomes in Patients with Atrial Fibrillation in the AVERROES Study

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Apixaban N = 2,807 n (%/year)</th>
<th>ASA N = 2,791 n (%/year)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke or systemic embolism*</td>
<td>51 (1.62)</td>
<td>113 (3.63)</td>
<td>0.45 (0.32, 0.62)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischaemic or unspecified</td>
<td>43 (1.37)</td>
<td>97 (3.11)</td>
<td>0.44 (0.31, 0.63)</td>
<td></td>
</tr>
<tr>
<td>Haemorrhagic</td>
<td>6 (0.19)</td>
<td>9 (0.28)</td>
<td>0.67 (0.24, 1.88)</td>
<td></td>
</tr>
<tr>
<td>Systemic embolism</td>
<td>2 (0.06)</td>
<td>13 (0.41)</td>
<td>0.15 (0.03, 0.68)</td>
<td></td>
</tr>
<tr>
<td>Stroke, systemic embolism, MI, or vascular death†</td>
<td>132 (4.21)</td>
<td>197 (6.35)</td>
<td>0.66 (0.53, 0.83)</td>
<td>0.003</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>24 (0.76)</td>
<td>28 (0.89)</td>
<td>0.86 (0.50, 1.48)</td>
<td></td>
</tr>
<tr>
<td>Vascular Death</td>
<td>84 (2.65)</td>
<td>96 (3.03)</td>
<td>0.87 (0.65, 1.17)</td>
<td></td>
</tr>
<tr>
<td>All-cause death†</td>
<td>111 (3.51)</td>
<td>140 (4.42)</td>
<td>0.79 (0.62, 1.02)</td>
<td>0.068</td>
</tr>
</tbody>
</table>

* Assessed by sequential testing strategy designed to control the overall type I error in the trial.
† Secondary endpoint.

There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 9).

Table 9: Bleeding Events in Patients with Atrial Fibrillation in the AVERROES Study

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Apixaban N = 2,798 n (%/year)</th>
<th>ASA N = 2,780 n (%/year)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major*</td>
<td>45 (1.41)</td>
<td>29 (0.92)</td>
<td>1.54 (0.96, 2.45)</td>
<td>0.0716</td>
</tr>
<tr>
<td>Fatal, n</td>
<td>5 (0.16)</td>
<td>5 (0.16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracranial, n</td>
<td>11 (0.34)</td>
<td>11 (0.35)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major + CRNM†</td>
<td>140 (4.46)</td>
<td>101 (3.24)</td>
<td>1.38 (1.07, 1.78)</td>
<td>0.0144</td>
</tr>
<tr>
<td>All</td>
<td>325 (10.85)</td>
<td>250 (8.32)</td>
<td>1.30 (1.10, 1.53)</td>
<td>0.0017</td>
</tr>
</tbody>
</table>

*Major bleeding defined per International Society on Thrombosis ad Haemostasis (ISTH) criteria.
† Clinically Relevant Non-Major

Patients undergoing cardioversion
EMANATE, an open-label, multi-center study, enrolled 1500 patients who were either oral anticoagulant naïve or pre-treated less than 48 hours, and scheduled for cardioversion for NVAF. Patients were randomized 1:1 to apixaban or to heparin and/or VKA for the prevention of cardiovascular events. Electrical and/or pharmacologic cardioversion was conducted after at least 5 doses of 5 mg twice daily apixaban (or 2.5 mg twice daily in selected patients (see section 4.2)) or at least 2 hours after a 10 mg loading dose (or a 5 mg loading dose in selected patients (see section 4.2)) if earlier cardioversion was required. In the apixaban group, 342 patients received a loading dose (331 patients received the 10 mg dose and 11 patients received the 5 mg dose).

There were no strokes (0%) in the apixaban group (n = 753) and 6 (0.80%) strokes in the heparin and/or VKA group (n = 747; RR 0.00, 95% CI 0.00, 0.64). All-cause death occurred in 2 patients (0.27%) in the apixaban group and 1 patient (0.13%) in the heparin and/or VKA group. No systemic embolism events were reported.

Major bleeding and CRNM bleeding events occurred in 3 (0.41%) and 11 (1.50%) patients, respectively, in the apixaban group, compared to 6 (0.83%) and 13 (1.80%) patients in the heparin and/or VKA group.

This exploratory study showed comparable efficacy and safety between apixaban and heparin and/or VKA treatment groups in the setting of cardioversion.

Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)
The clinical program (AMPLIFY: apixaban versus enoxaparin, AMPLIFY-EXT: apixaban versus placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY), and extended therapy for the prevention of recurrent DVT and/or PE following 6 to 12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT). Both studies were randomised, parallel-group, double-blind, multinational trials in patients with symptomatic proximal DVT or symptomatic PE. All the key safety and efficacy endpoints were adjudicated by an independent blinded committee.

AMPLIFY STUDY
In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR≥ 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.

The mean age was 56.9 years and 89.8% of randomised patients had unprovoked VTE events.

For patients randomised to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9. Apixaban showed a reduction in recurrent symptomatic VTE or VTE-related death across the different levels of center TTR; within the highest quartile of TTR according to center, the relative risk for apixaban vs enoxaparin/warfarin was 0.79 (95% CI, 0.39, 1.61).

In the study, apixaban was shown to be non-inferior to enoxaparin/warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death (see Table 10).

Table 10: Efficacy Results in the AMPLIFY Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban N=2,609 n (%)</th>
<th>Enoxaparin/Warfarin N=2,635 n (%)</th>
<th>Relative Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTE or VTE-related death</td>
<td>59 (2.3)</td>
<td>71 (2.7)</td>
<td>0.84 (0.60, 1.18)*</td>
</tr>
<tr>
<td>DVT</td>
<td>20 (0.7)</td>
<td>33 (1.2)</td>
<td></td>
</tr>
<tr>
<td>PE</td>
<td>27 (1.0)</td>
<td>23 (0.9)</td>
<td></td>
</tr>
<tr>
<td>VTE-related death</td>
<td>12 (0.4)</td>
<td>15 (0.6)</td>
<td></td>
</tr>
<tr>
<td>VTE or all-cause death</td>
<td>84 (3.2)</td>
<td>104 (4.0)</td>
<td>0.82 (0.61, 1.08)</td>
</tr>
<tr>
<td>VTE or CV-related death</td>
<td>61 (2.3)</td>
<td>77 (2.9)</td>
<td>0.80 (0.57, 1.11)</td>
</tr>
<tr>
<td>VTE, VTE-related death, or major bleeding</td>
<td>73 (2.8)</td>
<td>118 (4.5)</td>
<td>0.62 (0.47, 0.83)</td>
</tr>
</tbody>
</table>

* Noninferior compared to enoxaparin/warfarin (p-value <0.0001)

Apixaban efficacy in initial treatment of VTE was consistent between patients who were treated for a PE [Relative Risk 0.9; 95% CI (0.5, 1.6)] or DVT [Relative Risk 0.8; 95% CI (0.5, 1.3)]. Efficacy across subgroups, including age, gender, body mass index (BMI), renal function, extent of index PE, location of DVT thrombus, and prior parenteral heparin use was generally consistent.

The primary safety endpoint was major bleeding. In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value <0.0001] (see Table 11).
Table 11: Bleeding Results in the AMPLIFY Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban N=2,676</th>
<th>Enoxaparin/ Warfarin N=2,689</th>
<th>Relative Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Major</td>
<td>15 (0.6)</td>
<td>49 (1.8)</td>
<td>0.31 (0.17, 0.55)</td>
</tr>
<tr>
<td>Major + CRNM</td>
<td>115 (4.3)</td>
<td>261 (9.7)</td>
<td>0.44 (0.36, 0.55)</td>
</tr>
<tr>
<td>Minor</td>
<td>313 (11.7)</td>
<td>505 (18.8)</td>
<td>0.62 (0.54, 0.70)</td>
</tr>
<tr>
<td>All</td>
<td>402 (15.0)</td>
<td>676 (25.1)</td>
<td>0.59 (0.53, 0.66)</td>
</tr>
</tbody>
</table>

The adjudicated major bleeding and CRNM bleeding at any anatomical site were generally lower in the apixaban group as compared to the enoxaparin/warfarin group. Adjudicated ISTH major gastrointestinal bleeding occurred in 6 (0.2%) apixaban-treated patients and 17 (0.6%) enoxaparin/warfarin-treated patients.

AMPLIFY-EXT STUDY

In the AMPLIFY-EXT study a total of 2,482 patients were randomised to treatment with apixaban 2.5 mg twice daily orally, apixaban 5 mg twice daily orally, or placebo for 12 months after completing 6 to 12 months of initial anticoagulant treatment. Of these, 836 patients (33.7%) participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study.

The mean age was 56.7 years and 91.7% of randomised patients had unprovoked VTE events.

In the study, both doses of apixaban were statistically superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE) or all-cause death (see Table 12).

Table 12: Efficacy Results in the AMPLIFY-EXT Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban 2.5 mg (N=840)</th>
<th>Apixaban 5.0 mg (N=813)</th>
<th>Placebo (N=829)</th>
<th>Relative Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>Apix 2.5 mg vs. Placebo</td>
</tr>
<tr>
<td>Recurrent VTE or all-cause death</td>
<td>19 (2.3)</td>
<td>14 (1.7)</td>
<td>77 (9.3)</td>
<td>0.24 (0.15, 0.40)</td>
</tr>
<tr>
<td>DVT*</td>
<td>6 (0.7)</td>
<td>7 (0.9)</td>
<td>53 (6.4)</td>
<td></td>
</tr>
<tr>
<td>PE*</td>
<td>7 (0.8)</td>
<td>4 (0.5)</td>
<td>13 (1.6)</td>
<td></td>
</tr>
<tr>
<td>All-cause death</td>
<td>6 (0.7)</td>
<td>3 (0.4)</td>
<td>11 (1.3)</td>
<td></td>
</tr>
<tr>
<td>Recurrent VTE or VTE-related death</td>
<td>14 (1.7)</td>
<td>14 (1.7)</td>
<td>73 (8.8)</td>
<td>0.19 (0.11, 0.33)</td>
</tr>
<tr>
<td>Recurrent VTE or CV-related death</td>
<td>14 (1.7)</td>
<td>14 (1.7)</td>
<td>76 (9.2)</td>
<td>0.18 (0.10, 0.32)</td>
</tr>
<tr>
<td>Nonfatal DVT†</td>
<td>6 (0.7)</td>
<td>8 (1.0)</td>
<td>53 (6.4)</td>
<td>0.11 (0.05, 0.26)</td>
</tr>
<tr>
<td>Nonfatal PE‡</td>
<td>8 (1.0)</td>
<td>4 (0.5)</td>
<td>15 (1.8)</td>
<td>0.51</td>
</tr>
</tbody>
</table>
Apixaban efficacy for prevention of a recurrence of a VTE was maintained across subgroups, including age, gender, BMI, and renal function.

The primary safety endpoint was major bleeding during the treatment period. In the study, the incidence in major bleeding for both apixaban doses was not statistically different from placebo. There was no statistically significant difference in the incidence of major + CRNM, minor, and all bleeding between the apixaban 2.5 mg twice daily and placebo treatment groups (see Table 13).

Table 13: Bleeding Results in the AMPLIFY-EXT Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban 2.5 mg (N=840)</th>
<th>Apixaban 5.0 mg (N=811)</th>
<th>Placebo (N=826)</th>
<th>Relative Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Apix 2.5 mg vs. Placebo</td>
</tr>
<tr>
<td>Major</td>
<td>2 (0.2)</td>
<td>3 (0.4)</td>
<td>7 (0.8)</td>
<td>0.28 (0.06, 1.37)</td>
</tr>
<tr>
<td>Major + CRNM</td>
<td>27 (3.2)</td>
<td>35 (4.3)</td>
<td>22 (2.7)</td>
<td>1.20 (0.69, 2.10)</td>
</tr>
<tr>
<td>Minor</td>
<td>75 (8.9)</td>
<td>98 (12.1)</td>
<td>58 (7.0)</td>
<td>1.26 (0.91, 1.75)</td>
</tr>
<tr>
<td>All</td>
<td>94 (11.2)</td>
<td>121 (14.9)</td>
<td>74 (9.0)</td>
<td>1.24 (0.93, 1.65)</td>
</tr>
</tbody>
</table>

Adjudicated ISTH major gastrointestinal bleeding occurred in 1 (0.1%) apixaban-treated patient at the 5 mg twice daily dose, no patients at the 2.5 mg twice daily dose, and 1 (0.1%) placebo-treated patient.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Eliquis in one or more subsets of the paediatric population in venous and arterial embolism and thrombosis (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption

The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Apixaban is rapidly absorbed with maximum concentrations (C_{max}) appearing 3 to 4 hours after tablet intake. Intake with food does not affect apixaban AUC or C_{max} at the 10 mg dose. Apixaban can be taken with or without food.
Apixaban demonstrates linear pharmacokinetics with dose proportional increases in exposure for oral doses up to 10 mg. At doses ≥ 25 mg apixaban displays dissolution limited absorption with decreased bioavailability. Apixaban exposure parameters exhibit low to moderate variability reflected by a within-subject and inter-subject variability of ~20% CV and ~30% CV, respectively.

Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets suspended in 30 mL of water, exposure was comparable to exposure after oral administration of 2 whole 5 mg tablets. Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets with 30 g of apple puree, the $C_{\text{max}}$ and AUC were 21% and 16% lower, respectively, when compared to administration of 2 whole 5 mg tablets. The reduction in exposure is not considered clinically relevant.

Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of D5W and delivered via a nasogastric tube, exposure was similar to exposure seen in other clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose.

Given the predictable, dose-proportional pharmacokinetic profile of apixaban, the bioavailability results from the conducted studies are applicable to lower apixaban doses.

**Distribution**
Plasma protein binding in humans is approximately 87%. The volume of distribution (Vss) is approximately 21 litres.

**Biotransformation and elimination**
Apixaban has multiple routes of elimination. Of the administered apixaban dose in humans, approximately 25% was recovered as metabolites, with the majority recovered in faeces. Renal excretion of apixaban accounts for approximately 27% of total clearance. Additional contributions from biliary and direct intestinal excretion were observed in clinical and nonclinical studies, respectively.

Apixaban has a total clearance of about 3.3 L/h and a half-life of approximately 12 hours.

O-demethylation and hydroxylation at the 3-oxopiperidinyl moiety are the major sites of biotransformation. Apixaban is metabolised mainly via CYP3A4/5 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. Unchanged apixaban is the major drug-related component in human plasma with no active circulating metabolites present. Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP).

**Renal impairment**
There was no impact of impaired renal function on peak concentration of apixaban. There was an increase in apixaban exposure correlated to decrease in renal function, as assessed via measured creatinine clearance. In individuals with mild (creatinine clearance 51-80 mL/min), moderate (creatinine clearance 30-50 mL/min) and severe (creatinine clearance 15-29 mL/min) renal impairment, apixaban plasma concentrations (AUC) were increased 16, 29, and 44% respectively, compared to individuals with normal creatinine clearance. Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-FXa activity.

In subjects with end-stage renal disease (ESRD), the AUC of apixaban was increased by 36% when a single dose of apixaban 5 mg was administered immediately after haemodialysis, compared to that seen in subjects with normal renal function. Haemodialysis, started two hours after administration of a single dose of apixaban 5 mg, decreased apixaban AUC by 14% in these ESRD subjects, corresponding to an apixaban dialysis clearance of 18 mL/min. Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose.

**Hepatic impairment**
In a study comparing 8 subjects with mild hepatic impairment, Child-Pugh A score 5 (n = 6) and score 6 (n = 2), and 8 subjects with moderate hepatic impairment, Child-Pugh B score 7 (n = 6) and score 8 (n = 2), to 16 healthy control subjects, the single-dose pharmacokinetics and
Pharmacodynamics of apixaban 5 mg were not altered in subjects with hepatic impairment. Changes in anti-Factor Xa activity and INR were comparable between subjects with mild to moderate hepatic impairment and healthy subjects.

**Elderly**

Elderly patients (above 65 years) exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 32% higher and no difference in C\text{max}.

**Gender**

Exposure to apixaban was approximately 18% higher in females than in males.

**Ethnic origin and race**

The results across phase I studies showed no discernible difference in apixaban pharmacokinetics between White/Caucasian, Asian and Black/African American subjects. Findings from a population pharmacokinetic analysis in patients who received apixaban were generally consistent with the phase I results.

**Body weight**

Compared to apixaban exposure in subjects with body weight of 65 to 85 kg, body weight > 120 kg was associated with approximately 30% lower exposure and body weight < 50 kg was associated with approximately 30% higher exposure.

**Pharmacokinetic/pharmacodynamic relationship**

The pharmacokinetic/pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 – 50 mg). The relationship between apixaban plasma concentration and anti-Factor Xa activity was best described by a linear model. The PK/PD relationship observed in patients was consistent with that established in healthy subjects.

### 5.3 Preclinical safety data

Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, fertility and embryo-foetal development and juvenile toxicity.

The major observed effects in the repeated dose toxicity studies were those related to the pharmacodynamic action of apixaban on blood coagulation parameters. In the toxicity studies little to no increase of bleeding tendency was found. However, since this may be due to a lower sensitivity of the non-clinical species compared to humans, this result should be interpreted with caution when extrapolating to humans.

### 6. PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

**Tablet core:**
- Anhydrous lactose
- Microcrystalline cellulose (E460)
- Croscarmellose sodium
- Sodium laurilsulfate
- Magnesium stearate (E470b)

**Film coat:**
- Lactose monohydrate
- Hypromellose (E464)
- Titanium dioxide (E171)
Triacetin (E1518)
Yellow iron oxide (E172)

6.2 Incompatibilities
Not applicable

6.3 Shelf life
3 years

6.4 Special precautions for storage
This medicinal product does not require any special storage condition.

6.5 Nature and contents of container
Alu PVC/PVdC perforated unit dose blisters of 60x1 and 100x1 film-coated tablets.
Not all pack sizes may be marketed.

6.6 Special precautions for disposal
No special requirements.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORITY
Bristol-Myers Squibb/Pfizer EEIG,
Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex
UB8 1DH
United Kingdom

8. MARKETING AUTHORITY NUMBER(S)
EU/1/11/691/001
EU/1/11/691/002
EU/1/11/691/003
EU/1/11/691/004
EU/1/11/691/005
EU/1/11/691/013
EU/1/11/691/015

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORITY
Date of first authorisation: 18 May 2011
Date of latest renewal: 14 January 2016
10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
1. **NAME OF THE MEDICINAL PRODUCT**

   Eliquis 5 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

   Each film-coated tablet contains 5 mg apixaban.

   **Excipients with known effect**
   Each 5 mg film-coated tablet contains 102.86 mg lactose (see section 4.4).
   
   For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

   Film-coated tablet (tablet)
   Pink, oval tablets debossed with 894 on one side and 5 on the other side.

4. **CLINICAL PARTICULARS**

   **4.1 Therapeutic indications**

   Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).

   Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).

   **4.2 Posology and method of administration**

   **Posology**
   
   *Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)*
   The recommended dose of apixaban is 5 mg taken orally twice daily.

   *Dose reduction*
   The recommended dose of apixaban is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL (133 micromole/L).

   Therapy should be continued long-term.

   *Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)*
   The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily. As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g., recent surgery, trauma, immobilisation).

   The recommended dose of apixaban for the prevention of recurrent DVT and PE is 2.5 mg taken orally twice daily. When prevention of recurrent DVT and PE is indicated, the 2.5 mg twice daily dose should be initiated following completion of 6 months of treatment with apixaban 5 mg twice daily or with another anticoagulant, as indicated in Table 1 below (see also section 5.1).
Table 1:

<table>
<thead>
<tr>
<th></th>
<th>Dosing schedule</th>
<th>Maximum daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of DVT or PE</td>
<td>10 mg twice daily for the first 7 days</td>
<td>20 mg</td>
</tr>
<tr>
<td></td>
<td>followed by 5 mg twice daily</td>
<td>10 mg</td>
</tr>
<tr>
<td>Prevention of recurrent DVT and/or PE following completion of 6 months of treatment for DVT or PE</td>
<td>2.5 mg twice daily</td>
<td>5 mg</td>
</tr>
</tbody>
</table>

The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).

**Missed dose**
If a dose is missed, the patient should take Eliquis immediately and then continue with twice daily intake as before.

**Switching**
Switching treatment from parenteral anticoagulants to Eliquis (and vice versa) can be done at the next scheduled dose (see section 4.5). These medicinal products should not be administered simultaneously.

**Switching from vitamin K antagonist (VKA) therapy to Eliquis**
When converting patients from vitamin K antagonist (VKA) therapy to Eliquis, warfarin or other VKA therapy should be discontinued and Eliquis started when the international normalised ratio (INR) is < 2.

**Switching from Eliquis to VKA therapy**
When converting patients from Eliquis to VKA therapy, administration of Eliquis should be continued for at least 2 days after beginning VKA therapy. After 2 days of coadministration of Eliquis with VKA therapy, an INR should be obtained prior to the next scheduled dose of Eliquis. Coadministration of Eliquis and VKA therapy should be continued until the INR is ≥ 2.

**Renal impairment**
In patients with mild or moderate renal impairment, the following recommendations apply:

- for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), no dose adjustment is necessary (see section 5.2).

- for the prevention of stroke and systemic embolism in patients with NVAF and serum creatinine ≥1.5 mg/dL (133 micromole/L) associated with age ≥80 years or body weight ≤60 kg, a dose reduction is necessary and described above. In the absence of other criteria for dose reduction (age, body weight), no dose adjustment is necessary (see section 5.2).

In patients with severe renal impairment (creatinine clearance 15-29 mL/min) the following recommendations apply (see sections 4.4 and 5.2):

- for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) apixaban is to be used with caution;

- for the prevention of stroke and systemic embolism in patients with NVAF, patients should receive the lower dose of apixaban 2.5 mg twice daily.
In patients with creatinine clearance < 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.4 and 5.2).

**Hepatic impairment**
Eliquis is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).

It is not recommended in patients with severe hepatic impairment (see sections 4.4 and 5.2).

It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B). No dose adjustment is required in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).

Patients with elevated liver enzymes alanine aminotransferase (ALT)/aspartate aminotransferase (AST) >2 x ULN or total bilirubin ≥ 1.5 x ULN were excluded in clinical trials. Therefore Eliquis should be used with caution in this population (see sections 4.4 and 5.2). Prior to initiating Eliquis, liver function testing should be performed.

**Body weight**
VTEt - No dose adjustment required (see sections 4.4 and 5.2).
NVAF - No dose adjustment required, unless criteria for dose reduction are met (see *Dose reduction* at the beginning of section 4.2).

**Gender**
No dose adjustment required (see section 5.2).

**Elderly**
VTEt - No dose adjustment required (see sections 4.4 and 5.2).
NVAF - No dose adjustment required, unless criteria for dose reduction are met (see *Dose reduction* at the beginning of section 4.2).

**Patients undergoing cardioversion**
Apixaban can be initiated or continued in NVAF patients who may require cardioversion.

For patients not previously treated with anticoagulants, at least 5 doses of apixaban 5 mg twice daily (2.5 mg twice daily in patients who qualify for a dose reduction (see above sections *Dose reduction* and *Renal impairment*)) should be given before cardioversion to ensure adequate anticoagulation (see section 5.1).

If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily. The dosing regimen should be reduced to a 5 mg loading dose followed by 2.5 mg twice daily if the patient meets the criteria for dose reduction (see above sections *Dose reduction* and *Renal impairment*). The administration of the loading dose should be given at least 2 hours before cardioversion (see section 5.1).

Confirmation should be sought prior to cardioversion that the patient has taken apixaban as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.

**Paediatric population**
The safety and efficacy of Eliquis in children and adolescents below age 18 have not been established. No data are available.

**Method of administration**
Oral use
Eliquis should be swallowed with water, with or without food.
For patients who are unable to swallow whole tablets, Eliquis tablets may be crushed and suspended in water, or 5% dextrose in water (D5W), or apple juice or mixed with apple puree and immediately administered orally (see section 5.2). Alternatively, Eliquis tablets may be crushed and suspended in 60 mL of water or D5W and immediately delivered through a nasogastric tube (see section 5.2). Crushed Eliquis tablets are stable in water, D5W, apple juice, and apple puree for up to 4 hours.

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Active clinically significant bleeding.
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 5.2).
- Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
- Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

4.4 Special warnings and precautions for use

Haemorrhage risk
As with other anticoagulants, patients taking Eliquis are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Eliquis administration should be discontinued if severe haemorrhage occurs (see sections 4.8 and 4.9).

Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see section 5.1).

Interaction with other medicinal products affecting haemostasis
Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).

The concomitant use of Eliquis with antiplatelet agents increases the risk of bleeding (see section 4.5).

Care is to be taken if patients are treated concomitantly with non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid.

Following surgery, other platelet aggregation inhibitors are not recommended concomitantly with Eliquis (see section 4.5).

In patients with atrial fibrillation and conditions that warrant mono or dual antiplatelet therapy, a careful assessment of the potential benefits against the potential risks should be made before combining this therapy with Eliquis.

In a clinical trial of patients with atrial fibrillation, concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on
warfarin from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.1%) use of concomitant dual antiplatelet therapy.

In a clinical trial of high-risk post acute coronary syndrome patients, characterised by multiple cardiac and non-cardiac comorbidities, who received ASA or the combination of ASA and clopidogrel, a significant increase in risk of ISTH (International Society on Thrombosis and Haemostasis) major bleeding was reported for apixaban (5.13% per year) compared to placebo (2.04% per year).

**Use of thrombolytic agents for the treatment of acute ischemic stroke**
There is very limited experience with the use of thrombolytic agents for the treatment of acute ischemic stroke in patients administered apixaban.

**Patients with prosthetic heart valves**
Safety and efficacy of Eliquis have not been studied in patients with prosthetic heart valves, with or without atrial fibrillation. Therefore, the use of Eliquis is not recommended in this setting.

**Surgery and invasive procedures**
Eliquis should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding. This includes interventions for which the probability of clinically significant bleeding cannot be excluded or for which the risk of bleeding would be unacceptable.

Eliquis should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding. This includes interventions for which any bleeding that occurs is expected to be minimal, non-critical in its location or easily controlled.

If surgery or invasive procedures cannot be delayed, appropriate caution should be exercised, taking into consideration an increased risk of bleeding. This risk of bleeding should be weighed against the urgency of intervention.

Eliquis should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established (for cardioversion see section 4.2).

**Temporary discontinuation**
Discontinuing anticoagulants, including Eliquis, for active bleeding, elective surgery, or invasive procedures places patients at an increased risk of thrombosis. Lapses in therapy should be avoided and if anticoagulation with Eliquis must be temporarily discontinued for any reason, therapy should be restarted as soon as possible.

**Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy**
Eliquis is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of apixaban have not been established in these clinical situations.

**Patients with active cancer**
Efficacy and safety of apixaban in the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) in patients with active cancer have not been established.

**Patients with renal impairment**
Limited clinical data indicate that apixaban plasma concentrations are increased in patients with severe renal impairment (creatinine clearance 15-29 mL/min) which may lead to an increased bleeding risk. For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), apixaban is to be used with caution in patients with severe renal impairment (creatinine clearance 15-29 mL/min) (see sections 4.2 and 5.2).
For the prevention of stroke and systemic embolism in patients with NVAF, patients with severe renal impairment (creatinine clearance 15-29 mL/min), and patients with serum creatinine ≥ 1.5 mg/dL (133 micromole/L) associated with age ≥ 80 years or body weight ≤ 60 kg should receive the lower dose of apixaban 2.5 mg twice daily (see section 4.2);

In patients with creatinine clearance < 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.2 and 5.2).

**Elderly patients**

Increasing age may increase haemorrhagic risk (see section 5.2). Also, the co-administration of Eliquis with ASA in elderly patients should be used cautiously because of a potentially higher bleeding risk.

**Body weight**

Low body weight (< 60 kg) may increase haemorrhagic risk (see section 5.2).

**Patients with hepatic impairment**

Eliquis is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).

It is not recommended in patients with severe hepatic impairment (see section 5.2).

It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B) (see sections 4.2 and 5.2).

Patients with elevated liver enzymes ALT/AST > 2 x ULN or total bilirubin ≥ 1.5 x ULN were excluded in clinical trials. Therefore Eliquis should be used cautiously in this population (see section 5.2). Prior to initiating Eliquis, liver function testing should be performed.

**Interaction with inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp)**

The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir). These medicinal products may increase apixaban exposure by 2-fold (see section 4.5) or greater in the presence of additional factors that increase apixaban exposure (e.g., severe renal impairment).

**Interaction with inducers of both CYP3A4 and P-gp**

The concomitant use of Eliquis with strong CYP3A4 and P-gp inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital or St. John’s Wort) may lead to a ~50% reduction in apixaban exposure. In a clinical study in atrial fibrillation patients, diminished efficacy and a higher risk of bleeding were observed with coadministration of apixaban with strong inducers of both CYP3A4 and P-gp compared with using apixaban alone.

In patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp the following recommendations apply (see section 4.5):

- for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE, apixaban should be used with caution;

- for the treatment of DVT and treatment of PE, apixaban should not be used since efficacy may be compromised.

**Laboratory parameters**

Clotting tests [e.g., prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT)] are affected as expected by the mechanism of action of apixaban. Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability (see section 5.1).
Information about excipients
Eliquis contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

Inhibitors of CYP3A4 and P-gp
Coadministration of apixaban with ketoconazole (400 mg once a day), a strong inhibitor of both CYP3A4 and P-gp, led to a 2-fold increase in mean apixaban AUC and a 1.6-fold increase in mean apixaban C\text{max}.

The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see section 4.4).

Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (e.g., diltiazem, naproxen, clarithromycin, amiodarone, verapamil, quinidine) are expected to increase apixaban plasma concentration to a lesser extent. No dose adjustment for apixaban is required when coadministered with agents that are not strong inhibitors of both CYP3A4 and P-gp. For example, diltiazem (360 mg once a day), considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean apixaban AUC and a 1.3-fold increase in C\text{max}. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and C\text{max}, respectively. Clarithromycin (500 mg, twice a day), an inhibitor of P-gp and a strong inhibitor of CYP3A4, led to a 1.6-fold and 1.3-fold increase in mean apixaban AUC and C\text{max} respectively.

Inducers of CYP3A4 and P-gp
Coadministration of apixaban with rifampicin, a strong inducer of both CYP3A4 and P-gp, led to an approximate 54% and 42% decrease in mean apixaban AUC and C\text{max}, respectively. The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers (e.g., phenytoin, carbamazepine, phenobarbital or St. John’s Wort) may also lead to reduced apixaban plasma concentrations. No dose adjustment for apixaban is required during concomitant therapy with such medicinal products, however in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp apixaban should be used with caution for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE. Apixaban is not recommended for the treatment of DVT and PE in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp since efficacy may be compromised (see section 4.4).

Anticoagulants, platelet aggregation inhibitors and NSAIDs
Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).

After combined administration of enoxaparin (40 mg single dose) with apixaban (5 mg single dose), an additive effect on anti-Factor Xa activity was observed.

Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325 mg once a day.

Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel 75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.

Naproxen (500 mg), an inhibitor of P-gp, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and C\text{max}, respectively. Corresponding increases in clotting tests were observed for apixaban. No
changes were observed in the effect of naproxen on arachidonic acid-induced platelet aggregation and no clinically relevant prolongation of bleeding time was observed after concomitant administration of apixaban and naproxen.

Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplatelet agents are coadministered with apixaban. Eliquis should be used with caution when coadministered with NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk. A significant increase in bleeding risk was reported with the triple combination of apixaban, ASA and clopidogrel in a clinical study in patients with acute coronary syndrome (see section 4.4).

Medicinal products associated with serious bleeding are not recommended concomitantly with Eliquis, such as: thrombolytic agents, GPIIb/IIIa receptor antagonists, thienopyridines (e.g., clopidogrel), dipyridamole, dextran and sulfinpyrazone.

Other concomitant therapies
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coadministered with atenolol or famotidine. Coadministration of apixaban 10 mg with atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban. Following administration of the two medicinal products together, mean apixaban AUC and C_max were 15% and 18% lower than when administered alone. The administration of apixaban 10 mg with famotidine 40 mg had no effect on apixaban AUC or C_max.

Effect of apixaban on other medicinal products
In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 µM) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 µM) at concentrations that are significantly greater than peak plasma concentrations observed in patients. Apixaban did not induce CYP1A2, CYP2B6, CYP3A4/5 at a concentration up to 20 µM. Therefore, apixaban is not expected to alter the metabolic clearance of coadministered drugs that are metabolised by these enzymes. Apixaban is not a significant inhibitor of P-gp.

In studies conducted in healthy subjects, as described below, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, or atenolol.

Digoxin
Coadministration of apixaban (20 mg once a day) and digoxin (0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or C_max. Therefore, apixaban does not inhibit P-gp mediated substrate transport.

Naproxen
Coadministration of single doses of apixaban (10 mg) and naproxen (500 mg), a commonly used NSAID, did not have any effect on the naproxen AUC or C_max.

Atenolol
Coadministration of a single dose of apixaban (10 mg) and atenolol (100 mg), a common beta-blocker, did not alter the pharmacokinetics of atenolol.

Activated charcoal
Administration of activated charcoal reduces apixaban exposure (see section 4.9).

4.6 Fertility, pregnancy and lactation

Pregnancy
There are no data from the use of apixaban in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Apixaban is not recommended during pregnancy.
Breast-feeding
It is unknown whether apixaban or its metabolites are excreted in human milk. Available data in animals have shown excretion of apixaban in milk. In rat milk, a high milk to maternal plasma ratio ($C_{max}$ about 8, AUC about 30) was found, possibly due to active transport into the milk. A risk to newborns and infants cannot be excluded.

A decision must be made to either discontinue breast-feeding or to discontinue/abstain from apixaban therapy.

Fertility
Studies in animals dosed with apixaban have shown no effect on fertility (see section 5.3).

4.7 Effects on ability to drive and use machines
Eliquis has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile
The safety of apixaban has been investigated in 4 Phase III clinical studies including more than 15,000 patients: more than 11,000 patients in NVAF studies and more than 4,000 patients in the VTE treatment (VTEt) studies, for an average total exposure of 1.7 years and 221 days respectively (see section 5.1).

Common adverse reactions were haemorrhage, contusion, epistaxis, and haematoma (see Table 2 for adverse reaction profile and frequencies by indication).

In the NVAF studies, the overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in the apixaban vs warfarin study and 9.6% in the apixaban vs acetylsalicylic acid study. In the apixaban vs warfarin study the incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) with apixaban was 0.76%/year. The incidence of ISTH major intraocular bleeding with apixaban was 0.18%/year.

In the VTEt studies, the overall incidence of adverse reactions related to bleeding with apixaban was 15.6% in the apixaban vs enoxaparin/warfarin study and 13.3% in the apixaban vs placebo study (see section 5.1).

Tabulated list of adverse reactions
Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common (≥ 1/10) common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data) for NVAF and VTEt respectively.

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Prevention of stroke and systemic embolism in adult patients with NVAF, with one or more risk factors (NVAF)</th>
<th>Treatment of DVT and PE, and prevention of recurrent DVT and PE (VTEt)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity, allergic oedema and Anaphylaxis</td>
<td>Uncommon</td>
<td>-</td>
</tr>
<tr>
<td>Pruritus</td>
<td>Uncommon</td>
<td>Uncommon*</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>System Organ Class</td>
<td>Prevention of stroke and systemic embolism in adult patients with NVAF, with one or more risk factors (NVAF)</td>
<td>Treatment of DVT and PE, and prevention of recurrent DVT and PE (VTEt)</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>Brain haemorrhage</td>
<td>uncommon</td>
<td>rare</td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye haemorrhage (including conjunctival haemorrhage)</td>
<td>common</td>
<td>uncommon</td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemorrhage, haematoma</td>
<td>common</td>
<td>common</td>
</tr>
<tr>
<td>Intra-abdominal haemorrhage</td>
<td>uncommon</td>
<td>-</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis</td>
<td>common</td>
<td>common</td>
</tr>
<tr>
<td>Haemoptysis</td>
<td>uncommon</td>
<td>uncommon</td>
</tr>
<tr>
<td>Respiratory tract haemorrhage</td>
<td>rare</td>
<td>rare</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal haemorrhage</td>
<td>common</td>
<td>common</td>
</tr>
<tr>
<td>Haemorrhoidal haemorrhage, mouth haemorrhage</td>
<td>uncommon</td>
<td>-</td>
</tr>
<tr>
<td>Haematochezia</td>
<td>uncommon</td>
<td>uncommon</td>
</tr>
<tr>
<td>Rectal haemorrhage, gingival bleeding</td>
<td>common</td>
<td>common</td>
</tr>
<tr>
<td>Retroperitoneal haemorrhage</td>
<td>rare</td>
<td>-</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin rash</td>
<td>uncommon</td>
<td>-</td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematuria</td>
<td>common</td>
<td>common</td>
</tr>
<tr>
<td><strong>Reproductive system and breast disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal vaginal haemorrhage, urogenital haemorrhage</td>
<td>uncommon</td>
<td>uncommon</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application site bleeding</td>
<td>uncommon</td>
<td>-</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occult blood positive</td>
<td>uncommon</td>
<td>uncommon</td>
</tr>
<tr>
<td><strong>Injury, poisoning and procedural complications</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contusion</td>
<td>common</td>
<td>common</td>
</tr>
<tr>
<td>Traumatic haemorrhage, post procedural haemorrhage, incision site haemorrhage</td>
<td>uncommon</td>
<td>uncommon</td>
</tr>
</tbody>
</table>

* There were no occurrences of generalized pruritus in CV185057 (long term prevention of VTE)

The use of Eliquis may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may result in posthaemorrhagic anaemia. The signs, symptoms, and severity will vary according to the location and degree or extent of the bleeding (see sections 4.4 and 5.1).

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9  Overdose

There is no antidote to Eliquis. Overdose of apixaban may result in a higher risk of bleeding. In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. The initiation of appropriate treatment, e.g., surgical haemostasis or the transfusion of fresh frozen plasma should be considered.

In controlled clinical trials, orally-administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily (bid) for 7 days or 50 mg once daily (od) for 3 days) had no clinically relevant adverse effects.

In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20 mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively, and had no impact on \( C_{\text{max}} \). Mean half-life of apixaban decreased from 13.4 hours when apixaban was administered alone to 5.3 hours and 4.9 hours, respectively, when activated charcoal was administered 2 and 6 hours after apixaban. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.

If life-threatening bleeding cannot be controlled by the above measures, administration of prothrombin complex concentrates (PCCs) or recombinant factor VIIa may be considered. Reversal of Eliquis pharmacodynamic effects, as demonstrated by changes in the thrombin generation assay, was evident at the end of infusion and reached baseline values within 4 hours after the start of a 4-factor PCC 30 minute infusion in healthy subjects. However, there is no clinical experience with the use of 4-factor PCC products to reverse bleeding in individuals who have received Eliquis. Currently there is no experience with the use of recombinant factor VIIa in individuals receiving apixaban. Re-dosing of recombinant factor VIIa could be considered and titrated depending on improvement of bleeding.

Depending on local availability, a consultation of a coagulation expert should be considered in case of major bleedings.

Haemodialysis decreased apixaban AUC by 14% in subjects with end-stage renal disease (ESRD), when a single dose of apixaban 5 mg was administered orally. Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose.

5. PHARMACOLOGICAL PROPERTIES

5.1  Pharmacodynamic properties

Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF02

Mechanism of action
Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development. Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved haemostasis.

Pharmacodynamic effects
The pharmacodynamic effects of apixaban are reflective of the mechanism of action (FXa inhibition). As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected
therapeutic dose are small and subject to a high degree of variability. They are not recommended to assess the pharmacodynamic effects of apixaban. In the thrombin generation assay, apixaban reduced endogenous thrombin potential, a measure of thrombin generation in human plasma.

Apixaban also demonstrates anti-FXa activity as evident by reduction in Factor Xa enzyme activity in multiple commercial anti-FXa kits, however results differ across kits. Data from clinical trials are only available for the Rotachrom® Heparin chromogenic assay. Anti-FXa activity exhibits a close direct linear relationship with apixaban plasma concentration, reaching maximum values at the time of apixaban peak plasma concentrations. The relationship between apixaban plasma concentration and anti-FXa activity is approximately linear over a wide dose range of apixaban.

Table 3 below shows the predicted steady state exposure and anti-Factor Xa activity. In non-valvular atrial fibrillation patients taking apixaban for the prevention of stroke and systemic embolism, the results demonstrate a less than 1.7-fold fluctuation in peak-to-trough levels. In patients taking apixaban for the treatment of DVT and PE or prevention of recurrent DVT and PE, the results demonstrate a less than 2.2-fold fluctuation in peak-to-trough levels.

Table 3: Predicted Apixaban Steady-state Exposure and Anti-Xa Activity

<table>
<thead>
<tr>
<th></th>
<th>Apix. C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</th>
<th>Apix. C&lt;sub&gt;min&lt;/sub&gt; (ng/mL)</th>
<th>Apix. Anti-Xa Activity Max (IU/mL)</th>
<th>Apix. Anti-Xa Activity Min (IU/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevention of stroke and systemic embolism: NVAF</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5 mg twice daily*</td>
<td>123 [69, 221]</td>
<td>79 [34, 162]</td>
<td>1.8 [1.0, 3.3]</td>
<td>1.2 [0.51, 2.4]</td>
</tr>
<tr>
<td>5 mg twice daily</td>
<td>171 [91, 321]</td>
<td>103 [41, 230]</td>
<td>2.6 [1.4, 4.8]</td>
<td>1.5 [0.61, 3.4]</td>
</tr>
<tr>
<td><strong>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5 mg twice daily</td>
<td>67 [30, 153]</td>
<td>32 [11, 90]</td>
<td>1.0 [0.46, 2.5]</td>
<td>0.49 [0.17, 1.4]</td>
</tr>
<tr>
<td>5 mg twice daily</td>
<td>132 [59, 302]</td>
<td>63 [22, 177]</td>
<td>2.1 [0.91, 5.2]</td>
<td>1.0 [0.33, 2.9]</td>
</tr>
<tr>
<td>10 mg twice daily</td>
<td>251 [111, 572]</td>
<td>120 [41, 335]</td>
<td>4.2 [1.8, 10.8]</td>
<td>1.9 [0.64, 5.8]</td>
</tr>
</tbody>
</table>

* Dose adjusted population based on 2 of 3 dose reduction criteria in the ARISTOTLE study.

Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery.

Clinical efficacy and safety

Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)
A total of 23,799 patients were randomised in the clinical program (ARISTOTLE: apixaban versus warfarin, AVERROES: apixaban versus ASA) including 11,927 randomised to apixaban. The program was designed to demonstrate the efficacy and safety of apixaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and one or more additional risk factors, such as:

- prior stroke or transient ischaemic attack (TIA)
- age ≥ 75 years
- hypertension
- diabetes mellitus
- symptomatic heart failure (NYHA Class ≥ II)
ARISTOTLE STUDY
In the ARISTOTLE study a total of 18,201 patients were randomised to double-blind treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [4.7%], see section 4.2) or warfarin (target INR range 2.0-3.0), patients were exposed to study drug for a mean of 20 months. The mean age was 69.1 years, the mean CHADS2 score was 2.1, 18.9% of patients had prior stroke or TIA.

In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic or ischaemic) and systemic embolism (see Table 4) compared with warfarin.

Table 4: Efficacy Outcomes in Patients with Atrial Fibrillation in the ARISTOTLE Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban</th>
<th>Warfarin</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=9,120</td>
<td>N=9,081</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n (%/yr)</td>
<td>n (%/yr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke or systemic embolism</td>
<td>212 (1.27)</td>
<td>265 (1.60)</td>
<td>0.79 (0.66, 0.95)</td>
<td>0.0114</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischaemic or unspecified</td>
<td>162 (0.97)</td>
<td>175 (1.05)</td>
<td>0.92 (0.74, 1.13)</td>
<td></td>
</tr>
<tr>
<td>Haemorrhagic</td>
<td>40 (0.24)</td>
<td>78 (0.47)</td>
<td>0.51 (0.35, 0.75)</td>
<td></td>
</tr>
<tr>
<td>Systemic embolism</td>
<td>15 (0.09)</td>
<td>17 (0.10)</td>
<td>0.87 (0.44, 1.75)</td>
<td></td>
</tr>
</tbody>
</table>

For patients randomised to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%.

Apixaban showed a reduction of stroke and systemic embolism compared to warfarin across the different levels of center TTR; within the highest quartile of TTR according to center, the hazard ratio for apixaban vs warfarin was 0.73 (95% CI, 0.38, 1.40).

Key secondary endpoints of major bleeding and all cause death were tested in a pre-specified hierarchical testing strategy to control the overall type 1 error in the trial. Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 5). With improving monitoring of INR the observed benefits of apixaban compared to warfarin regarding all cause death diminish.

Table 5: Secondary Endpoints in Patients with Atrial Fibrillation in the ARISTOTLE Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban</th>
<th>Warfarin</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 9,088</td>
<td>N = 9,052</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n (%/year)</td>
<td>n (%/year)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bleeding Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major*</td>
<td>327 (2.13)</td>
<td>462 (3.09)</td>
<td>0.69 (0.60, 0.80)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Fatal</td>
<td>10 (0.06)</td>
<td>37 (0.24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracranial</td>
<td>52 (0.33)</td>
<td>122 (0.80)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major + CRNM†</td>
<td>613 (4.07)</td>
<td>877 (6.01)</td>
<td>0.68 (0.61, 0.75)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>All</td>
<td>2356 (18.1)</td>
<td>3060 (25.8)</td>
<td>0.71 (0.68, 0.75)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Other Endpoints</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause death</td>
<td>603 (3.52)</td>
<td>669 (3.94)</td>
<td>0.89 (0.80, 1.00)</td>
<td>0.0465</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>90 (0.53)</td>
<td>102 (0.61)</td>
<td>0.88 (0.66, 1.17)</td>
<td></td>
</tr>
</tbody>
</table>

* Major bleeding defined per International Society on Thrombosis and Haemostasis (ISTH) criteria.
† Clinically Relevant Non-Major

The overall discontinuation rate due to adverse reactions was 1.8% for apixaban and 2.6% for warfarin in the ARISTOTLE study.
The efficacy results for prespecified subgroups, including CHADS₂ score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the primary efficacy results for the overall population studied in the trial.

The incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) was 0.76%/year with apixaban and 0.86%/year with warfarin.

The major bleeding results for prespecified subgroups including CHADS₂ score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the results for the overall population studied in the trial.

**AVERROES STUDY**

In the AVERROES study a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomised to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%], see section 4.2) or ASA. ASA was given at a once daily dose of 81 mg (64%), 162 (26.9%), 243 (2.1%), or 324 mg (6.6%) at the discretion of the investigator. Patients were exposed to study drug for a mean of 14 months. The mean age was 69.9 years, the mean CHADS₂ score was 2.0 and 13.6% of patients had prior stroke or TIA.

Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS₂ score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medicinal product instruction (15.0%), and difficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%).

AVERROES was stopped early based on a recommendation by the independent Data Monitoring Committee due to clear evidence of reduction of stroke and systemic embolism with an acceptable safety profile.

The overall discontinuation rate due to adverse reactions was 1.5% for apixaban and 1.3% for ASA in the AVERROES study.

In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 6) compared to ASA.

**Table 6: Key Efficacy Outcomes in Patients with Atrial Fibrillation in the AVERROES Study**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Apixaban N = 2,807 n (%/year)</th>
<th>ASA N = 2,791 n (%/year)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke or systemic embolism*</td>
<td>51 (1.62)</td>
<td>113 (3.63)</td>
<td>0.45 (0.32, 0.62)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischaemic or unspecified</td>
<td>43 (1.37)</td>
<td>97 (3.11)</td>
<td>0.44 (0.31, 0.63)</td>
<td></td>
</tr>
<tr>
<td>Haemorrhagic</td>
<td>6 (0.19)</td>
<td>9 (0.28)</td>
<td>0.67 (0.24, 1.88)</td>
<td></td>
</tr>
<tr>
<td>Systemic embolism</td>
<td>2 (0.06)</td>
<td>13 (0.41)</td>
<td>0.15 (0.03, 0.68)</td>
<td></td>
</tr>
<tr>
<td>Stroke, systemic embolism, MI, or vascular death*†</td>
<td>132 (4.21)</td>
<td>197 (6.35)</td>
<td>0.66 (0.53, 0.83)</td>
<td>0.003</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>24 (0.76)</td>
<td>28 (0.89)</td>
<td>0.86 (0.50, 1.48)</td>
<td></td>
</tr>
<tr>
<td>Vascular Death</td>
<td>84 (2.65)</td>
<td>96 (3.03)</td>
<td>0.87 (0.65, 1.17)</td>
<td></td>
</tr>
<tr>
<td>All-cause death†</td>
<td>111 (3.51)</td>
<td>140 (4.42)</td>
<td>0.79 (0.62, 1.02)</td>
<td>0.068</td>
</tr>
</tbody>
</table>

* Assessed by sequential testing strategy designed to control the overall type I error in the trial
† Secondary endpoint.
There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 7).

### Table 7: Bleeding Events in Patients with Atrial Fibrillation in the AVERROES Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban</th>
<th>ASA</th>
<th>Hazard Ratio (95%CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 2,798</td>
<td>N = 2,780</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major*</td>
<td>45 (1.41)</td>
<td>29 (0.92)</td>
<td>1.54 (0.96, 2.45)</td>
<td>0.0716</td>
</tr>
<tr>
<td>Fatal, n</td>
<td>5 (0.16)</td>
<td>5 (0.16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracranial, n</td>
<td>11 (0.34)</td>
<td>11 (0.35)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major + CRNM†</td>
<td>140 (4.46)</td>
<td>101 (3.24)</td>
<td>1.38 (1.07, 1.78)</td>
<td>0.0144</td>
</tr>
<tr>
<td>All</td>
<td>325 (10.85)</td>
<td>250 (8.32)</td>
<td>1.30 (1.10, 1.53)</td>
<td>0.0017</td>
</tr>
</tbody>
</table>

*Major bleeding defined per International Society on Thrombosis ad Haemostasis (ISTH) criteria.
† Clinically Relevant Non-Major

**Patients undergoing cardioversion**

EMANATE, an open-label, multi-center study, enrolled 1500 patients who were either oral anticoagulant naive or pre-treated less than 48 hours, and scheduled for cardioversion for NVAF. Patients were randomized 1:1 to apixaban or to heparin and/or VKA for the prevention of cardiovascular events. Electrical and/or pharmacologic cardioversion was conducted after at least 5 doses of 5 mg twice daily apixaban (or 2.5 mg twice daily in selected patients (see section 4.2)) or at least 2 hours after a 10 mg loading dose (or a 5 mg loading dose in selected patients (see section 4.2)) if earlier cardioversion was required. In the apixaban group, 342 patients received a loading dose (331 patients received the 10 mg dose and 11 patients received the 5 mg dose).

There were no strokes (0%) in the apixaban group (n = 753) and 6 (0.80%) strokes in the heparin and/or VKA group (n = 747; RR 0.00, 95% CI 0.00, 0.64). All-cause death occurred in 2 patients (0.27%) in the apixaban group and 1 patient (0.13%) in the heparin and/or VKA group. No systemic embolism events were reported.

Major bleeding and CRNM bleeding events occurred in 3 (0.41%) and 11 (1.50%) patients, respectively, in the apixaban group, compared to 6 (0.83%) and 13 (1.80%) patients in the heparin and/or VKA group.

This exploratory study showed comparable efficacy and safety between apixaban and heparin and/or VKA treatment groups in the setting of cardioversion.

**Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)**

The clinical program (AMPLIFY: apixaban versus enoxaparin/warfarin, AMPLIFY-EXT: apixaban versus placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY), and extended therapy for the prevention of recurrent DVT and/or PE following 6 to 12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT). Both studies were randomised, parallel-group, double-blind, multinational trials in patients with symptomatic proximal DVT or symptomatic PE. All the key safety and efficacy endpoints were adjudicated by an independent blinded committee.

**AMPLIFY STUDY**

In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR≥ 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.

The mean age was 56.9 years and 89.8% of randomised patients had unprovoked VTE events. For patients randomised to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9. Apixaban showed a reduction in recurrent symptomatic VTE or VTE-related death across the different levels of center TTR; within the highest quartile of TTR according to center, the relative risk for apixaban vs enoxaparin/warfarin was 0.79 (95% CI, 0.39, 1.61).
In the study, apixaban was shown to be non-inferior to enoxaparin/warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death (see Table 8).

Table 8: Efficacy Results in the AMPLIFY Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban N=2,609 n (%)</th>
<th>Enoxaparin/ Warfarin N=2,635 n (%)</th>
<th>Relative Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTE or VTE-related death</td>
<td>59 (2.3)</td>
<td>71 (2.7)</td>
<td>0.84 (0.60, 1.18)*</td>
</tr>
<tr>
<td>DVT</td>
<td>20 (0.7)</td>
<td>33 (1.2)</td>
<td></td>
</tr>
<tr>
<td>PE</td>
<td>27 (1.0)</td>
<td>23 (0.9)</td>
<td></td>
</tr>
<tr>
<td>VTE-related death</td>
<td>12 (0.4)</td>
<td>15 (0.6)</td>
<td></td>
</tr>
<tr>
<td>VTE or all-cause death</td>
<td>84 (3.2)</td>
<td>104 (4.0)</td>
<td>0.82 (0.61, 1.08)</td>
</tr>
<tr>
<td>VTE or CV-related death</td>
<td>61 (2.3)</td>
<td>77 (2.9)</td>
<td>0.80 (0.57, 1.11)</td>
</tr>
<tr>
<td>VTE, VTE-related death, or major bleeding</td>
<td>73 (2.8)</td>
<td>118 (4.5)</td>
<td>0.62 (0.47, 0.83)</td>
</tr>
</tbody>
</table>

* Noninferior compared to enoxaparin/warfarin (p-value < 0.0001)

Apixaban efficacy in initial treatment of VTE was consistent between patients who were treated for a PE [Relative Risk 0.9; 95% CI (0.5, 1.6)] or DVT [Relative Risk 0.8; 95% CI (0.5, 1.3)]. Efficacy across subgroups, including age, gender, body mass index (BMI), renal function, extent of index PE, location of DVT thrombus, and prior parenteral heparin use was generally consistent.

The primary safety endpoint was major bleeding. In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value < 0.0001] (see Table 9).

Table 9: Bleeding Results in the AMPLIFY Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban N=2,676 n (%)</th>
<th>Enoxaparin/ Warfarin N=2,689 n (%)</th>
<th>Relative Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major</td>
<td>15 (0.6)</td>
<td>49 (1.8)</td>
<td>0.31 (0.17, 0.55)</td>
</tr>
<tr>
<td>Major + CRNM</td>
<td>115 (4.3)</td>
<td>261 (9.7)</td>
<td>0.44 (0.36, 0.55)</td>
</tr>
<tr>
<td>Minor</td>
<td>313 (11.7)</td>
<td>505 (18.8)</td>
<td>0.62 (0.54, 0.70)</td>
</tr>
<tr>
<td>All</td>
<td>402 (15.0)</td>
<td>676 (25.1)</td>
<td>0.59 (0.53, 0.66)</td>
</tr>
</tbody>
</table>

The adjudicated major bleeding and CRNM bleeding at any anatomical site were generally lower in the apixaban group as compared to the enoxaparin/warfarin group. Adjudicated ISTH major gastrointestinal bleeding occurred in 6 (0.2%) apixaban-treated patients and 17 (0.6%) enoxaparin/warfarin-treated patients.
**AMPLIFY-EXT STUDY**

In the AMPLIFY-EXT study a total of 2,482 patients were randomised to treatment with apixaban 2.5 mg twice daily orally, apixaban 5 mg twice daily orally, or placebo for 12 months after completing 6 to 12 months of initial anticoagulant treatment. Of these, 836 patients (33.7%) participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study. The mean age was 56.7 years and 91.7% of randomised patients had unprovoked VTE events.

In the study, both doses of apixaban were statistically superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE) or all-cause death (see Table 10).

### Table 10: Efficacy Results in the AMPLIFY-EXT Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban 2.5 mg (N=840)</th>
<th>Apixaban 5.0 mg (N=813)</th>
<th>Placebo (N=829)</th>
<th>Relative Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Apix 2.5 mg vs. Placebo</td>
<td>Apix 5.0 mg vs. Placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent VTE or all-cause death</td>
<td>19 (2.3)</td>
<td>14 (1.7)</td>
<td>77 (9.3)</td>
<td>0.24 (0.15, 0.40)¥</td>
</tr>
<tr>
<td>DVT*</td>
<td>6 (0.7)</td>
<td>7 (0.9)</td>
<td>53 (6.4)</td>
<td>0.19 (0.11, 0.33)¥</td>
</tr>
<tr>
<td>PE*</td>
<td>7 (0.8)</td>
<td>4 (0.5)</td>
<td>13 (1.6)</td>
<td>0.19 (0.11, 0.33)¥</td>
</tr>
<tr>
<td>All-cause death</td>
<td>6 (0.7)</td>
<td>3 (0.4)</td>
<td>11 (1.3)</td>
<td>0.19 (0.11, 0.33)¥</td>
</tr>
<tr>
<td>Recurrent VTE or VTE-related death</td>
<td>14 (1.7)</td>
<td>14 (1.7)</td>
<td>73 (8.8)</td>
<td>0.19 (0.11, 0.33)¥</td>
</tr>
<tr>
<td>Recurrent VTE or CV-related death</td>
<td>14 (1.7)</td>
<td>14 (1.7)</td>
<td>76 (9.2)</td>
<td>0.18 (0.10, 0.32)</td>
</tr>
<tr>
<td>Nonfatal DVT†</td>
<td>6 (0.7)</td>
<td>8 (1.0)</td>
<td>53 (6.4)</td>
<td>0.11 (0.05, 0.26)</td>
</tr>
<tr>
<td>Nonfatal PE†</td>
<td>8 (1.0)</td>
<td>4 (0.5)</td>
<td>15 (1.8)</td>
<td>0.51 (0.22, 1.21)</td>
</tr>
<tr>
<td>VTE-related death</td>
<td>2 (0.2)</td>
<td>3 (0.4)</td>
<td>7 (0.8)</td>
<td>0.28 (0.06, 1.37)</td>
</tr>
</tbody>
</table>

¥ p-value < 0.0001
* For patients with more than one event contributing to the composite endpoint, only the first event was reported (e.g., if a subject experienced both a DVT and then a PE, only the DVT was reported)
† Individual subjects could experience more than one event and be represented in both classifications

Apixaban efficacy for prevention of a recurrence of a VTE was maintained across subgroups, including age, gender, BMI, and renal function.

The primary safety endpoint was major bleeding during the treatment period. In the study, the incidence in major bleeding for both apixaban doses was not statistically different from placebo. There was no statistically significant difference in the incidence of major + CRNM, minor, and all bleeding between the apixaban 2.5 mg twice daily and placebo treatment groups (see Table 11).
Table 11: Bleeding Results in the AMPLIFY-EXT Study

<table>
<thead>
<tr>
<th></th>
<th>Apixaban 2.5 mg (N=840)</th>
<th>Apixaban 5.0 mg (N=811)</th>
<th>Placebo (N=826)</th>
<th>Apixaban 2.5 mg vs. Placebo</th>
<th>Apixaban 5.0 mg vs. Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 (0.2)</td>
<td>1 (0.1)</td>
<td>4 (0.5)</td>
<td>0.49 (0.09, 2.64)</td>
<td>0.25 (0.03, 2.24)</td>
</tr>
<tr>
<td>Major</td>
<td>27 (3.2)</td>
<td>35 (4.3)</td>
<td>22 (2.7)</td>
<td>1.20 (0.69, 2.10)</td>
<td>1.62 (0.96, 2.73)</td>
</tr>
<tr>
<td>Major +</td>
<td>75 (8.9)</td>
<td>98 (12.1)</td>
<td>58 (7.0)</td>
<td>1.26 (0.91, 1.75)</td>
<td>1.70 (1.25, 2.31)</td>
</tr>
<tr>
<td>Minor</td>
<td>94 (11.2)</td>
<td>121 (14.9)</td>
<td>74 (9.0)</td>
<td>1.24 (0.93, 1.65)</td>
<td>1.65 (1.26, 2.16)</td>
</tr>
</tbody>
</table>

Adjudicated ISTH major gastrointestinal bleeding occurred in 1 (0.1%) apixaban-treated patient at the 5 mg twice daily dose, no patients at the 2.5 mg twice daily dose, and 1 (0.1%) placebo-treated patient.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Eliquis in one or more subsets of the paediatric population in venous and arterial embolism and thrombosis (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption

The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Apixaban is rapidly absorbed with maximum concentrations (C\text{max}) appearing 3 to 4 hours after tablet intake. Intake with food does not affect apixaban AUC or C\text{max} at the 10 mg dose. Apixaban can be taken with or without food.

Apixaban demonstrates linear pharmacokinetics with dose proportional increases in exposure for oral doses up to 10 mg. At doses ≥ 25 mg apixaban displays dissolution limited absorption with decreased bioavailability. Apixaban exposure parameters exhibit low to moderate variability reflected by a within-subject and inter-subject variability of ~20% CV and ~30% CV, respectively.

Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets suspended in 30 mL of water, exposure was comparable to exposure after oral administration of 2 whole 5 mg tablets. Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets with 30 g of apple puree, the C\text{max} and AUC were 21% and 16% lower, respectively, when compared to administration of 2 whole 5 mg tablets. The reduction in exposure is not considered clinically relevant.

Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of D5W and delivered via a nasogastric tube, exposure was similar to exposure seen in other clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose.

Given the predictable, dose-proportional pharmacokinetic profile of apixaban, the bioavailability results from the conducted studies are applicable to lower apixaban doses.
Distribution
Plasma protein binding in humans is approximately 87%. The volume of distribution (Vss) is approximately 21 litres.

Biotransformation and elimination
Apixaban has multiple routes of elimination. Of the administered apixaban dose in humans, approximately 25% was recovered as metabolites, with the majority recovered in faeces. Renal excretion of apixaban accounts for approximately 27% of total clearance. Additional contributions from biliary and direct intestinal excretion were observed in clinical and nonclinical studies, respectively.

Apixaban has a total clearance of about 3.3 L/h and a half-life of approximately 12 hours.

O-demethylation and hydroxylation at the 3-oxopiperidiny moiety are the major sites of biotransformation. Apixaban is metabolised mainly via CYP3A4/5 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. Unchanged apixaban is the major drug-related component in human plasma with no active circulating metabolites present. Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP).

Renal impairment
There was no impact of impaired renal function on peak concentration of apixaban. There was an increase in apixaban exposure correlated to decrease in renal function, as assessed via measured creatinine clearance. In individuals with mild (creatinine clearance 51-80 mL/min), moderate (creatinine clearance 30-50 mL/min) and severe (creatinine clearance 15-29 mL/min) renal impairment, apixaban plasma concentrations (AUC) were increased 16, 29, and 44% respectively, compared to individuals with normal creatinine clearance. Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-FXa activity.

In subjects with end-stage renal disease (ESRD), the AUC of apixaban was increased by 36% when a single dose of apixaban 5 mg was administered immediately after haemodialysis, compared to that seen in subjects with normal renal function. Haemodialysis, started two hours after administration of a single dose of apixaban 5 mg, decreased apixaban AUC by 14% in these ESRD subjects, corresponding to an apixaban dialysis clearance of 18 mL/min. Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose.

Hepatic impairment
In a study comparing 8 subjects with mild hepatic impairment, Child-Pugh A score 5 (n = 6) and score 6 (n = 2), and 8 subjects with moderate hepatic impairment, Child-Pugh B score 7 (n = 6) and score 8 (n = 2), to 16 healthy control subjects, the single-dose pharmacokinetics and pharmacodynamics of apixaban 5 mg were not altered in subjects with hepatic impairment. Changes in anti-Factor Xa activity and INR were comparable between subjects with mild to moderate hepatic impairment and healthy subjects.

Elderly
Elderly patients (above 65 years) exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 32% higher and no difference in Cmax.

Gender
Exposure to apixaban was approximately 18% higher in females than in males.

Ethnic origin and race
The results across phase I studies showed no discernible difference in apixaban pharmacokinetics between White/Caucasian, Asian and Black/African American subjects. Findings from a population pharmacokinetic analysis in patients who received apixaban were generally consistent with the phase I results.
Body weight
Compared to apixaban exposure in subjects with body weight of 65 to 85 kg, body weight > 120 kg was associated with approximately 30% lower exposure and body weight < 50 kg was associated with approximately 30% higher exposure.

Pharmacokinetic/pharmacodynamic relationship
The pharmacokinetic/pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 – 50 mg). The relationship between apixaban plasma concentration and anti-Factor Xa activity was best described by a linear model. The PK/PD relationship observed in patients was consistent with that established in healthy subjects.

5.3 Preclinical safety data
Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, fertility and embryo-foetal development and juvenile toxicity.

The major observed effects in the repeated dose toxicity studies were those related to the pharmacodynamic action of apixaban on blood coagulation parameters. In the toxicity studies little to no increase of bleeding tendency was found. However, since this may be due to a lower sensitivity of the non-clinical species compared to humans, this result should be interpreted with caution when extrapolating to humans.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Tablet core:
Anhydrous lactose
Microcrystalline cellulose (E460)
Croscarmellose sodium
Sodium laurilsulfate
Magnesium stearate (E470b)

Film coat:
Lactose monohydrate
Hypermellose (E464)
Titanium dioxide (E171)
Triacetin (E1518)
Iron oxide red (E172)

6.2 Incompatibilities
Not applicable

6.3 Shelf life
3 years

6.4 Special precautions for storage
This medicinal product does not require any special storage condition.
6.5 Nature and contents of container

Alu-PVC/PVdC blisters. Cartons of 14, 20, 28, 56, 60, 168 and 200 film-coated tablets. Alu-PVC/PVdC perforated unit dose blisters of 100x1 film coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Bristol-Myers Squibb/Pfizer EEIG,
Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex
UB8 1DH
United Kingdom

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/11/691/006
EU/1/11/691/007
EU/1/11/691/008
EU/1/11/691/009
EU/1/11/691/010
EU/1/11/691/011
EU/1/11/691/012
EU/1/11/691/014

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 18 May 2011
Date of latest renewal: 14 January 2016

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Bristol-Myers Squibb S.r.l
Loc. Fontana del Ceraso
03012 Anagni (FR)
Italy

Pfizer Manufacturing Deutschland GmbH
Betriebsstätte Freiburg
Mooswaldallee 1
79090 Freiburg
Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

- Additional risk minimisation measures

The MAH shall provide an educational pack prior to launch, targeting all physicians who are expected to prescribe/use Eliquis. Key safety messages have to be included in the educational pack for all indications.
The educational pack is aimed at increasing awareness about the potential risk of bleeding during treatment with Eliquis and providing guidance on how to manage that risk.

The MAH must agree the content and format of the educational material, together with a communication plan, with the national competent authority in each Member State prior to distribution of the educational pack in their territory.

The physician educational pack should contain:
• The Summary of Product Characteristics
• Prescriber Guide
• Patient Alert Cards

The Prescriber Guide should contain the following key safety messages:
• Details of populations potentially at higher risk of bleeding
• Recommended dosages and guidance on the posology for different indications
• Recommendations for dose adjustment in at risk populations, including renal or hepatic impairment patients
• Guidance regarding switching from or to Eliquis treatment
• Guidance regarding surgery or invasive procedure, and temporary discontinuation
• Management of overdose situations and haemorrhage
• The use of coagulation tests and their interpretation
• That all patients should be provided with a Patient alert card and be counselled about signs or symptoms of bleeding and when to seek attention from a health care provider
• Importance of treatment compliance
• Necessity to carry the Patient alert card with them at all times
• The need to inform Health Care Professionals that they are taking Eliquis if they need to have any surgery or invasive procedure.

The Patient alert card should contain the following key safety messages:
• Signs or symptoms of bleeding and when to seek attention from a health care provider.
• Importance of treatment compliance
• Necessity to carry the Patient alert card with them at all times
• The need to inform Health Care Professionals that they are taking Eliquis if they need to have any surgery or invasive procedure.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON 2.5 mg

1. NAME OF THE MEDICINAL PRODUCT

Eliquis 2.5 mg film-coated tablets
apixaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 2.5 mg apixaban.

3. LIST OF EXCIPIENTS

Contains lactose. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

10 film-coated tablets
20 film-coated tablets
60 film-coated tablets
60 x 1 film-coated tablets
100 x 1 film-coated tablets
168 film-coated tablets
200 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bristol-Myers Squibb/Pfizer EEIG,
Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex
UB8 1DH
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/11/691/001
EU/1/11/691/002
EU/1/11/691/003
EU/1/11/691/004
EU/1/11/691/005
EU/1/11/691/013
EU/1/11/691/015

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Eliquis 2.5 mg

17. UNIQUE IDENTIFIER - 2D BARCODE

2D barcode carrying the unique identifier included

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
<NN:>
**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**BLISTER 2.5 mg**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><strong>NAME OF THE MEDICINAL PRODUCT</strong></td>
</tr>
<tr>
<td></td>
<td>Eliquis 2.5 mg tablets</td>
</tr>
<tr>
<td></td>
<td>apixaban</td>
</tr>
<tr>
<td>2.</td>
<td><strong>NAME OF THE MARKETING AUTHORISATION HOLDER</strong></td>
</tr>
<tr>
<td></td>
<td>Bristol-Myers Squibb/Pfizer EEIG</td>
</tr>
<tr>
<td>3.</td>
<td><strong>EXPIRY DATE</strong></td>
</tr>
<tr>
<td></td>
<td>EXP</td>
</tr>
<tr>
<td>4.</td>
<td><strong>BATCH NUMBER</strong></td>
</tr>
<tr>
<td></td>
<td>Lot</td>
</tr>
<tr>
<td>5.</td>
<td><strong>OTHER</strong></td>
</tr>
<tr>
<td>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>BLISTER 2.5 mg (Symbol)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliquis 2.5 mg tablets</td>
</tr>
<tr>
<td>apixaban</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb/Pfizer EEIG</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td>sun as symbol</td>
</tr>
<tr>
<td>moon as symbol</td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON 5 mg

1. **NAME OF THE MEDICINAL PRODUCT**

   Eliquis 5 mg film-coated tablets
   apixaban

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each film-coated tablet contains 5 mg apixaban.

3. **LIST OF EXCIPIENTS**

   Contains lactose. See leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**

   14 film-coated tablets
   20 film-coated tablets
   28 film-coated tablets
   56 film-coated tablets
   60 film-coated tablets
   100x 1 film-coated tablets
   168 film-coated tablets
   200 film-coated tablets

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Read the package leaflet before use.
   For oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP
9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bristol-Myers Squibb/Pfizer EEIG,
Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex
UB8 1DH
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/11/691/006
EU/1/11/691/007
EU/1/11/691/008
EU/1/11/691/009
EU/1/11/691/010
EU/1/11/691/011
EU/1/11/691/012
EU/1/11/691/014

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Eliquis 5 mg

17. UNIQUE IDENTIFIER - 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
<NN:>
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLISTER 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliquis 5 mg tablets</td>
</tr>
<tr>
<td>apixaban</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb/Pfizer EEIG</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
</table>
Eliquis (apixaban)

Patient Alert Card

Carry this card with you at all times

Show this card to your pharmacist, dentist and any other healthcare professionals that treat you.

I am under anticoagulation treatment with Eliquis (apixaban) to prevent blood clots

Please complete this section or ask your doctor to do it
Name:
Birth Date:
Indication:
Dose: mg twice daily
Doctor's Name:
Doctor's telephone:

Information for patients

- Take Eliquis regularly as instructed. If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule.
- Do not stop taking Eliquis without talking to your doctor, as you are at risk of suffering from a stroke or other complications.
- Eliquis helps to thin your blood. However, this may increase your risk of bleeding.
- Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood.
- If the bleeding does not stop on its own, seek medical attention immediately.
- If you need surgery, inform your doctor that you are taking Eliquis.

Information for healthcare professionals

- Eliquis (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- Eliquis may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with Eliquis does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) – see SmPC.
B. PACKAGE LEAFLET
Package leaflet: Information for the user

Eliquis 2.5 mg film-coated tablets
Apixaban

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Eliquis is and what it is used for
2. What you need to know before you take Eliquis
3. How to take Eliquis
4. Possible side effects
5. How to store Eliquis
6. Contents of the pack and other information

1. What Eliquis is and what it is used for

Eliquis contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting.

Eliquis is used in adults:
- to prevent blood clots (deep vein thrombosis [DVT]) from forming after hip or knee replacement operations. After an operation to the hip or knee you may be at a higher risk of developing blood clots in your leg veins. This can cause the legs to swell, with or without pain. If a blood clot travels from your leg to your lungs, it can block blood flow causing breathlessness, with or without chest pain. This condition (pulmonary embolism) can be life-threatening and requires immediate medical attention.

- to prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor. Blood clots may break off and travel to the brain and lead to a stroke or to other organs and prevent normal blood flow to that organ (also known as a systemic embolism). A stroke can be life-threatening and requires immediate medical attention.

- to treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.

2. What you need to know before you take Eliquis

Do not take Eliquis if:
- you are allergic to apixaban or any of the other ingredients of this medicine (listed in section 6)
- you are bleeding excessively
- you have a disease in an organ of the body that increases the risk of serious bleeding (such as an active or a recent ulcer of your stomach or bowel, recent bleeding in your brain)
- you have a liver disease which leads to increased risk of bleeding (hepatic coagulopathy)
- you are taking medicines to prevent blood clotting (e.g., warfarin, rivaroxaban, dabigatran or heparin), except when changing anticoagulant treatment or while having a venous or arterial line and you get heparin through this line to keep it open.

**Warnings and precautions**

Talk to your doctor, pharmacist or nurse before you take this medicine if you have any of the following:
- an increased risk of bleeding, such as:
  - bleeding disorders, including conditions resulting in reduced platelet activity
  - very high blood pressure, not controlled by medical treatment
  - you are older than 75 years
  - you weigh 60 kg or less

- a severe kidney disease or if you are on dialysis
- a liver problem or a history of liver problems
  Eliquis will be used with caution in patients with signs of altered liver function.
- had a tube (catheter) or an injection into your spinal column (for anaesthesia or pain reduction), your doctor will tell you to take Eliquis 5 hours or more after catheter removal
- if you have a prosthetic heart valve
- if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned

If you need to have surgery or a procedure which may cause bleeding, your doctor might ask you to temporarily stop taking this medicine for a short while. If you are not sure whether a procedure may cause bleeding ask your doctor.

**Children and adolescents**

Eliquis is not recommended in children and adolescents under 18 years of age.

**Other medicines and Eliquis**

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.

Some medicines may increase the effects of Eliquis and some may decrease its effects. Your doctor will decide, if you should be treated with Eliquis when taking these medicines and how closely you should be monitored.

The following medicines may increase the effects of Eliquis and increase the chance for unwanted bleeding:
- some medicines for fungal infections (e.g., ketoconazole, etc.)
- some antiviral medicines for HIV / AIDS (e.g., ritonavir)
- other medicines that are used to reduce blood clotting (e.g., enoxaparin, etc.)
- anti-inflammatory or pain medicines (e.g., acetylsalicylic acid or naproxen). Especially, if you are older than 75 years and are taking acetylsalicylic acid, you may have an increased chance of bleeding.
- medicines for high blood pressure or heart problems (e.g., diltiazem)

The following medicines may reduce the ability of Eliquis to help prevent blood clots from forming:
- medicines to prevent epilepsy or seizures (e.g., phenytoin, etc.)
- St John’s Wort (a herbal supplement used for depression)
- medicines to treat tuberculosis or other infections (e.g., rifampicin)
Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.

The effects of Eliquis on pregnancy and the unborn child are not known. You should not take Eliquis if you are pregnant. Contact your doctor immediately if you become pregnant while taking Eliquis.

It is not known if Eliquis passes into human breast milk. Ask your doctor, pharmacist or nurse for advice before taking this medicine while breast-feeding. They will advise you to either stop breast-feeding or to stop/not start taking Eliquis.

Driving and using machines

Eliquis has not been shown to impair your ability to drive or use machines.

Eliquis contains lactose (a type of sugar).

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Eliquis

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.

Dose

Swallow the tablet with a drink of water. Eliquis can be taken with or without food. Try to take the tablets at the same times every day to have the best treatment effect.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Eliquis. The tablet may be crushed and mixed with water, or 5% dextrose in water, or apple juice or apple puree, immediately before you take it.

Instructions for crushing:

- Crush the tablets with a pestle and mortar.
- Transfer all the powder carefully into a suitable container then mix the powder with a little e.g., 30 mL (2 tablespoons), water or one of the other liquids mentioned above to make a mixture.
- Swallow the mixture.
- Rinse the pestle and mortar you used for crushing the tablet and the container, with a little water or one of the other liquids (e.g., 30 mL), and swallow the rinse.

If necessary, your doctor may also give you the crushed Eliquis tablet mixed in 60 mL of water or 5% dextrose in water, through a nasogastric tube.

Take Eliquis as recommended for the following:

To prevent blood clots from forming after hip or knee replacement operations.

The recommended dose is one tablet of Eliquis 2.5 mg twice a day.

For example, one in the morning and one in the evening.

You should take the first tablet 12 to 24 hours after your operation.

If you have had a major hip operation you will usually take the tablets for 32 to 38 days

If you have had a major knee operation you will usually take the tablets for 10 to 14 days
To prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.

The recommended dose is one tablet of Eliquis 5 mg twice a day.

The recommended dose is one tablet of Eliquis 2.5 mg twice a day if:
- you have severely reduced kidney function
- two or more of the following apply to you:
  - your blood test results suggest poor kidney function (value of serum creatinine is 1.5 mg/dL (133 micromole/L) or greater)
  - you are 80 years old or older
  - your weight is 60 kg or lower.

The recommended dose is one tablet twice a day, for example, one in the morning and one in the evening. Your doctor will decide how long you must continue treatment for.

To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs

The recommended dose is two tablets of Eliquis 5 mg twice a day for the first 7 days, for example, two in the morning and two in the evening.

After 7 days the recommended dose is one tablet of Eliquis 5 mg twice a day, for example, one in the morning and one in the evening.

For preventing blood clots from re-occurring following completion of 6 months of treatment

The recommended dose is one tablet of Eliquis 2.5 mg twice a day for example, one in the morning and one in the evening.

Your doctor will decide how long you must continue treatment for.

Your doctor might change your anticoagulant treatment as follows:

- Changing from Eliquis to anticoagulant medicines
  Stop taking Eliquis. Start treatment with the anticoagulant medicines (for example heparin) at the time you would have taken the next tablet.

- Changing from anticoagulant medicines to Eliquis
  Stop taking the anticoagulant medicines. Start treatment with Eliquis at the time you would have had the next dose of anticoagulant medicine, then continue as normal.

- Changing from treatment with anticoagulant containing vitamin K antagonist (e.g., warfarin) to Eliquis
  Stop taking the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to start taking Eliquis.

- Changing from Eliquis to anticoagulant treatment containing vitamin K antagonist (e.g., warfarin).
  If your doctor tells you that you have to start taking the medicine containing a vitamin K antagonist, continue to take Eliquis for at least 2 days after your first dose of the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to stop taking Eliquis.

Patients undergoing cardioversion

If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take Eliquis at the times your doctor tells you, to prevent blood clots in blood vessels in your brain and other blood vessels in your body.

If you take more Eliquis than you should
Tell your doctor immediately if you have taken more than the prescribed dose of Eliquis. Take the medicine pack with you, even if there are no tablets left.

If you take more Eliquis than recommended, you may have an increased risk of bleeding. If bleeding occurs, surgery or blood transfusions may be required.

If you forget to take Eliquis

- Take the dose as soon as you remember and:
  - take the next dose of Eliquis at the usual time
  - then continue as normal.

If you are not sure what to do or have missed more than one dose, ask your doctor, pharmacist or nurse.

If you stop taking Eliquis

Do not stop taking Eliquis without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Eliquis can be given for three different medical conditions. The known side effects and how frequently they occur for each of these medical conditions may differ and are listed separately below. For these conditions, the most common general side effect of Eliquis is bleeding which may be potentially life threatening and require immediate medical attention.

The following side effects are known if you take Eliquis to prevent blood clots from forming after hip or knee replacement operations.

Common side effects (may affect up to 1 in 10 people)

- Anaemia which may cause tiredness or paleness
- Bleeding including:
  - blood in the urine (that stains the urine pink or red)
  - bruising and swelling
  - vaginal bleeding
- Nausea (feeling sick)

Uncommon side effects (may affect up to 1 in 100 people)

- Reduced number of platelets in your blood (which can affect clotting)
- Bleeding including:
  - bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion)
  - bleeding in your stomach, bowel or blood in the stools
  - blood found in the urine
  - bleeding from your nose
- Low blood pressure which may make you feel faint or have a quickened heartbeat
- Blood tests may show:
  - abnormal liver function
  - an increase in some liver enzymes
- an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.

- Itching

**Rare side effects (may affect up to 1 in 1,000 people)**

- Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. **Contact your doctor immediately** if you experience any of these symptoms.
- Bleeding:
  - into a muscle
  - in your eyes
  - from your gums and blood in your spit when coughing
  - from your rectum

The following side effects are known if you take Eliquis to prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.

**Common side effects (may affect up to 1 in 10 people)**

Bleeding including:
- in your eyes
- in your stomach, bowel or dark/black blood in the stools
- blood found in the urine on laboratory testing
- from your nose
- from your gums
- bruising and swelling

**Uncommon side effects (may affect up to 1 in 100 people)**

Bleeding including:
- in your brain or in your spinal column
- in your mouth or blood in your spit when coughing
- into your abdomen, into the rectum or from the vagina
- bright/red blood in the stools
- bleeding occurring after any operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site
- Itching
- Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. **Contact your doctor immediately** if you experience any of these symptoms.

**Rare side effects (may affect up to 1 in 1,000 people)**

- bleeding in your lungs or your throat
- bleeding into the space behind your abdominal cavity

The following side effects are known if you take Eliquis to treat or prevent re-occurrence of blood clots in the veins of your legs and blood clots in the blood vessels of your lungs.

**Common side effects (may affect up to 1 in 10 people)**

Bleeding including:
- from your nose
- from your gums
- blood in the urine (that stains the urine pink or red)
- bruising and swelling
- in your stomach, your bowel, into the rectum

**Uncommon side effects (may affect up to 1 in 100 people)**

Bleeding including:
- in your eyes and bruise of the eyes
- in your mouth or blood in your spit when coughing
- dark/black blood in the stools
- into the uterus or from the vagina
- tests showing blood in the stools or in the urine
- bruising and swelling of a wound or injection site
- Itching

**Rare side effects (may affect up to 1 in 1,000 people)**

- abnormal tendency to spontaneous bleeding, loss of red blood cells due to bleeding

Bleeding including:
- in your brain
- in your abdomen, lungs or in the membrane surrounding the heart

**Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Eliquis**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

**6. Contents of the pack and other information**

**What Eliquis contains**

- The active substance is apixaban. Each tablet contains 2.5 mg of apixaban.
- The other ingredients are:
  - Tablet core: lactose anhydrous (see section 2), microcrystalline cellulose, croscarmellose sodium, sodium laurilsulfate, magnesium stearate (E470b).
  - Film coat: lactose monohydrate (see section 2), hypromellose (E464), titanium dioxide (E171), triacetin, yellow iron oxide (E172)

**What Eliquis looks like and contents of the pack**

The film-coated tablets are yellow, round and marked with “893” on one side and “2½” on the other side.
- They come in blisters in cartons of 10, 20, 60, 168 and 200 film-coated tablets.
- Unit dose blisters in cartons of 60 x 1 and 100 x 1 film-coated tablets for delivery in hospitals are also available.

Not all pack sizes may be marketed.

**Patient Alert Card: handling information**

Inside the Eliquis pack together with the package leaflet you will find a Patient Alert Card or your doctor might give you a similar card.

This Patient Alert Card includes information that will be helpful to you and alert other doctors that you are taking Eliquis. **You should keep this card with you at all times.**

1. Take the card
2. Separate your language as needed (this is facilitated by the perforated edges)
3. Complete the following sections or ask your doctor to do it:
   - Name:
   - Birth Date:
   - Indication:
   - Dose: ........mg twice daily
   - Doctor's Name:
   - Doctor's telephone:
4. Fold the card and keep it with you at all times

**Marketing Authorisation Holder**

Bristol-Myers Squibb/Pfizer EEIG,
Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex
UB8 1DH - United Kingdom

**Manufacturer**

Bristol-Myers Squibb S.r.l
Loc. Fontana del Ceraso
03012 Anagni (FR)
Italy

Pfizer Manufacturing Deutschland GmbH
Betriebsstätte Freiburg
Mooswaldallee 1
79090 Freiburg
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**Belgique/Belgie/Belgien**
N.V. Bristol-Myers Squibb Belgium S.A.
Tél/Tel: + 32 2 352 76 11

**Lietuva**
Pfizer Luxembourg SARL filialas Lietuvoje
Tel. +3705 2514000

**България**

Luxembourg/Luxemburg
<table>
<thead>
<tr>
<th>Country</th>
<th>Address</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>България</td>
<td>Пфайзер Люксембург САРЛ, Клон България</td>
<td>+359 2 970 4333</td>
</tr>
<tr>
<td>Прага</td>
<td>Pfizer PFE, spol. s r.o.</td>
<td>+420-283-004-111</td>
</tr>
<tr>
<td>Дания</td>
<td>Bristol-Myers Squibb</td>
<td>+45 45 93 05 06</td>
</tr>
<tr>
<td>Германия</td>
<td>Bristol-Myers Squibb GmbH &amp; Co. KGaA</td>
<td>+ 49 89 121 42-0</td>
</tr>
<tr>
<td>Чешская Республика</td>
<td>Pfizer Luxembourg SARL Eesti filialal</td>
<td>+372 666 7500</td>
</tr>
<tr>
<td>Эстония</td>
<td>Pfizer Luxembourg SARL Eesti filialal</td>
<td>+372 666 7500</td>
</tr>
<tr>
<td>Греция</td>
<td>Pfizer ΕΛΛΑΣ A.E.</td>
<td>+30 210 67 85 800</td>
</tr>
<tr>
<td>Испания</td>
<td>Bristol-Myers Squibb, S.A.</td>
<td>+ 34 91 456 53 00</td>
</tr>
<tr>
<td>Франция</td>
<td>Bristol-Myers Squibb SARL</td>
<td>+33 (0) 1 58 83 84 96</td>
</tr>
<tr>
<td>Хорватия</td>
<td>Pfizer Croatia d.o.</td>
<td>+385 1 3908 777</td>
</tr>
<tr>
<td>Ирландия</td>
<td>Bristol-Myers Squibb Pharmaceuticals uc</td>
<td>+ 353 (0) 1 483 3625</td>
</tr>
<tr>
<td>Исландия</td>
<td>Icepharma hf.</td>
<td>+354 540 8000</td>
</tr>
<tr>
<td>Италия</td>
<td>Bristol-Myers Squibb S.r.l.</td>
<td>+39 06 50 39 61</td>
</tr>
<tr>
<td>Кипр</td>
<td>Pfizer ΕΛΛΑΣ A.E. (CYPRUS BRANCH)</td>
<td>+357 22 817690</td>
</tr>
<tr>
<td>Латвия</td>
<td>Pfizer Luxembourg SARL filiāle Latvijā</td>
<td>+371 670 35 775</td>
</tr>
<tr>
<td>Литва</td>
<td>N.V. Bristol-Myers Squibb Belgium S.A.</td>
<td>+32 2 352 76 11</td>
</tr>
<tr>
<td>Венгрия</td>
<td>Pfizer Kft.</td>
<td>+36 1 488 37 00</td>
</tr>
<tr>
<td>Мальта</td>
<td>V.J. Salomone Pharma Ltd.</td>
<td>+356 21 22 01 74</td>
</tr>
<tr>
<td>Нидерландии</td>
<td>Bristol-Myers Squibb B.V.</td>
<td>+31 (0)30 300 2222</td>
</tr>
<tr>
<td>Норвегия</td>
<td>Bristol-Myers Squibb Norway Ltd</td>
<td>+47 67 55 53 50</td>
</tr>
<tr>
<td>Австрия</td>
<td>Bristol-Myers Squibb GesmbH</td>
<td>+43 1 60 14 30</td>
</tr>
<tr>
<td>Польша</td>
<td>Pfizer România S.R.L.</td>
<td>+40 21 207 28 00</td>
</tr>
<tr>
<td>Португалия</td>
<td>Bristol-Myers Squibb Farmacêutica Portuguesa, S.A.</td>
<td>+351 21 440 70 00</td>
</tr>
<tr>
<td>Румыния</td>
<td>Pfizer Luxembourg SARL</td>
<td>+386 (0) 1 52 11 400</td>
</tr>
<tr>
<td>Словакия</td>
<td>Pfizer Luxembourg SARL, organizačná zložka</td>
<td>+421-2-3355 5500</td>
</tr>
<tr>
<td>Словения</td>
<td>Pfizer Luxembourg SARL</td>
<td>+358 9 251 21 230</td>
</tr>
<tr>
<td>Швеция</td>
<td>Oy Bristol-Myers Squibb (Finland) Ab</td>
<td>+46 8 704 71 00</td>
</tr>
<tr>
<td>Швеция</td>
<td>Bristol-Myers Squibb Pharmaceuticals Ltd</td>
<td>+44 (0800) 731 1736</td>
</tr>
</tbody>
</table>
This leaflet was last revised in {MM/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Package leaflet: Information for the user

Eliquis 5 mg film-coated tablets
Apixaban

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Eliquis is and what it is used for
2. What you need to know before you take Eliquis
3. How to take Eliquis
4. Possible side effects
5. How to store Eliquis
6. Contents of the pack and other information

1. What Eliquis is and what it is used for

Eliquis contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting.

Eliquis is used in adults:
- to prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor. Blood clots may break off and travel to the brain and lead to a stroke or to other organs and prevent normal blood flow to that organ (also known as a systemic embolism). A stroke can be life-threatening and requires immediate medical attention.
- to treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.

2. What you need to know before you take Eliquis

Do not take Eliquis if:
- you are allergic to apixaban or any of the other ingredients of this medicine (listed in section 6)
- you are bleeding excessively
- you have a disease in an organ of the body that increases the risk of serious bleeding (such as an active or a recent ulcer of your stomach or bowel, recent bleeding in your brain)
- you have a liver disease which leads to increased risk of bleeding (hepatic coagulopathy)
- you are taking medicines to prevent blood clotting (e.g., warfarin, rivaroxaban, dabigatran or heparin), except when changing anticoagulant treatment or while having a venous or arterial line and you get heparin through this line to keep it open.
Warnings and precautions

Talk to your doctor, pharmacist or nurse before you take this medicine if you have any of the following:
- an increased risk of bleeding, such as:
  - bleeding disorders, including conditions resulting in reduced platelet activity
  - very high blood pressure, not controlled by medical treatment
  - you are older than 75 years
  - you weigh 60 kg or less
- a severe kidney disease or if you are on dialysis
- a liver problem or a history of liver problems
  Eliquis will be used with caution in patients with signs of altered liver function.
- if you have a prosthetic heart valve
- if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned

If you need to have surgery or a procedure which may cause bleeding, your doctor might ask you to temporarily stop taking this medicine for a short while. If you are not sure whether a procedure may cause bleeding ask your doctor.

Children and adolescents

Eliquis is not recommended in children and adolescents under 18 years of age.

Other medicines and Eliquis

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.

Some medicines may increase the effects of Eliquis and some may decrease its effects. Your doctor will decide, if you should be treated with Eliquis when taking these medicines and how closely you should be monitored.

The following medicines may increase the effects of Eliquis and increase the chance for unwanted bleeding:
- some medicines for fungal infections (e.g., ketoconazole, etc.)
- some antiviral medicines for HIV / AIDS (e.g., ritonavir)
- other medicines that are used to reduce blood clotting (e.g., enoxaparin, etc.)
- anti-inflammatory or pain medicines (e.g., acetylsalicylic acid or naproxen). Especially, if you are older than 75 years and are taking acetylsalicylic acid, you may have an increased chance of bleeding.
- medicines for high blood pressure or heart problems (e.g., diltiazem)

The following medicines may reduce the ability of Eliquis to help prevent blood clots from forming:
- medicines to prevent epilepsy or seizures (e.g., phenytoin, etc.)
- St John’s Wort (a herbal supplement used for depression)
- medicines to treat tuberculosis or other infections (e.g., rifampicin)

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.
The effects of Eliquis on pregnancy and the unborn child are not known. You should not take Eliquis if you are pregnant. **Contact your doctor immediately** if you become pregnant while taking Eliquis.

It is not known if Eliquis passes into human breast milk. Ask your doctor, pharmacist or nurse for advice before taking this medicine while breast-feeding. They will advise you to either stop breast-feeding or to stop/not start taking Eliquis.

**Driving and using machines**

Eliquis has not been shown to impair your ability to drive or use machines.

**Eliquis contains lactose (a type of sugar).**

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. **How to take Eliquis**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.

**Dose**

Swallow the tablet with a drink of water. Eliquis can be taken with or without food. Try to take the tablets at the same times every day to have the best treatment effect.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Eliquis. The tablet may be crushed and mixed with water, or 5% dextrose in water, or apple juice or apple puree, immediately before you take it.

**Instructions for crushing:**

- Crush the tablets with a pestle and mortar.
- Transfer all the powder carefully into a suitable container then mix the powder with a little e.g., 30 mL (2 tablespoons), water or one of the other liquids mentioned above to make a mixture.
- Swallow the mixture.
- Rinse the pestle and mortar you used for crushing the tablet and the container, with a little water or one of the other liquids (e.g., 30 mL), and swallow the rinse.

If necessary, your doctor may also give you the crushed Eliquis tablet mixed in 60 mL of water or 5% dextrose in water, through a nasogastric tube.

**Take Eliquis as recommended for the following:**

To prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.

The recommended dose is one tablet of Eliquis 5 mg twice a day.
The recommended dose is one tablet of Eliquis 2.5 mg twice a day if:

- you have severely reduced kidney function
- two or more of the following apply to you:
  - your blood test results suggest poor kidney function (value of serum creatinine is 1.5 mg/dL (133 micromole/L) or greater)
  - you are 80 years old or older
  - your weight is 60 kg or lower.

The recommended dose is one tablet twice a day, for example, one in the morning and one in the evening.

Your doctor will decide how long you must continue treatment for.

To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs

The recommended dose is two tablets of Eliquis 5 mg twice a day for the first 7 days, for example, two in the morning and two in the evening.

After 7 days the recommended dose is one tablet of Eliquis 5 mg twice a day, for example, one in the morning and one in the evening.

For preventing blood clots from re-occurring following completion of 6 months of treatment

The recommended dose is one tablet of Eliquis 2.5 mg twice a day for example, one in the morning and one in the evening.

Your doctor will decide how long you must continue treatment for.

**Your doctor might change your anticoagulant treatment as follows:**

- **Changing from Eliquis to anticoagulant medicines**
  Stop taking Eliquis. Start treatment with the anticoagulant medicines (for example heparin) at the time you would have taken the next tablet.

- **Changing from anticoagulant medicines to Eliquis**
  Stop taking the anticoagulant medicines. Start treatment with Eliquis at the time you would have had the next dose of anticoagulant medicine, then continue as normal.

- **Changing from treatment with anticoagulant containing vitamin K antagonist (e.g., warfarin) to Eliquis**
  Stop taking the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to start taking Eliquis.

- **Changing from Eliquis to anticoagulant treatment containing vitamin K antagonist (e.g., warfarin).**
  If your doctor tells you that you have to start taking the medicine containing a vitamin K antagonist, continue to take Eliquis for at least 2 days after your first dose of the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to stop taking Eliquis.

**Patients undergoing cardioversion**

If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take Eliquis at the times your doctor tells you, to prevent blood clots in blood vessels in your brain and other blood vessels in your body.

**If you take more Eliquis than you should**

Tell your doctor immediately if you have taken more than the prescribed dose of Eliquis. Take the medicine pack with you, even if there are no tablets left.
If you take more Eliquis than recommended, you may have an increased risk of bleeding. If bleeding occurs, surgery or blood transfusions may be required.

If you forget to take Eliquis

- Take the dose as soon as you remember and:
  - take the next dose of Eliquis at the usual time
  - then continue as normal.

If you are not sure what to do or have missed more than one dose, ask your doctor, pharmacist or nurse.

If you stop taking Eliquis

Do not stop taking Eliquis without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common general side effect of Eliquis is bleeding which may be potentially life threatening and require immediate medical attention.

The following side effects are known if you take Eliquis to prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.

Common side effects (may affect up to 1 in 10 people)

Bleeding including:
- in your eyes
- in your stomach, bowel or dark/black blood in the stools
- blood found in the urine on laboratory testing
- from your nose
- from your gums
- bruising and swelling

Uncommon side effects (may affect up to 1 in 100 people)

Bleeding including:
- in your brain or in your spinal column
- in your mouth or blood in your spit when coughing
- into your abdomen, into the rectum or from the vagina
- bright/red blood in the stools
- bleeding occurring after any operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site
- Itching
- Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms.
Rare side effects (may affect up to 1 in 1,000 people)

- bleeding in your lungs or your throat
- bleeding into the space behind your abdominal cavity

The following side effects are known if you take Eliquis to treat or prevent re-occurrence of blood clots in the veins of your legs and blood clots in the blood vessels of your lungs.

Common side effects (may affect up to 1 in 10 people)

Bleeding including:
- from your nose
- from your gums
- blood in the urine (that stains the urine pink or red)
- bruising and swelling
- in your stomach, your bowel, into the rectum

Uncommon side effects (may affect up to 1 in 100 people)

Bleeding including:
- in your eyes and bruise of the eyes
- in your mouth or blood in your spit when coughing
- dark/black blood in the stools
- into the uterus or from the vagina
- tests showing blood in the stools or in the urine
- bruising and swelling of a wound or injection site
- Itching

Rare side effects (may affect up to 1 in 1,000 people)

- abnormal tendency to spontaneous bleeding, loss of red blood cells due to bleeding

Bleeding including:
- in your brain
- in your abdomen, lungs or in the membrane surrounding the heart

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Eliquis

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information

What Eliquis contains

• The active substance is apixaban. Each tablet contains 5 mg of apixaban.
• The other ingredients are:
  - Tablet core: lactose anhydrous (see section 2), microcrystalline cellulose, croscarmellose sodium, sodium laurilsulfate, magnesium stearate (E470b).
  - Film coat: lactose monohydrate (see section 2), hypromellose (E464), titanium dioxide (E171), triacetin, red iron oxide (E172).

What Eliquis looks like and contents of the pack

The film coated tablets are pink, oval and marked with “894” on one side and “5” on the other side.

- They come in blisters in cartons of 14, 20, 28, 56, 60, 168 and 200 film-coated tablets.
- Unit dose blisters in cartons of 100 x 1 film-coated tablets for delivery in hospitals are also available.

Not all pack sizes may be marketed.

Patient Alert Card: handling information

Inside the Eliquis pack together with the package leaflet you will find a Patient Alert Card or your doctor might give you a similar card.
This Patient Alert Card includes information that will be helpful to you and alert other doctors that you are taking Eliquis. You should keep this card with you at all times.

1. Take the card
2. Separate your language as needed (this is facilitated by the perforated edges)
3. Complete the following sections or ask your doctor to do it:
   - Name:
   - Birth Date:
   - Indication:
   - Dose: ........mg twice daily
   - Doctor’s Name:
   - Doctor’s telephone:
4. Fold the card and keep it with you at all times

Marketing Authorisation Holder

Bristol-Myers Squibb/Pfizer EEIG,
Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex
UB8 1DH - United Kingdom

Manufacturer

Bristol-Myers Squibb S.r.l
Loc. Fontana del Ceraso
03012 Anagni (FR)
Italy
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**Belgique/Belgie/Belgien**
N.V. Bristol-Myers Squibb Belgium S.A.
Tél/Tel: + 32 2 352 76 11

**България**
Пфайзер Люксембург САРЛ, Клон България
Тел.: +359 2 970 4333

**Česká republika**
Pfizer PFE, spol. s r.o.
Tel: +420-283-004-111

**Danmark**
Bristol-Myers Squibb
Tlf: + 45 45 93 05 06

**Deutschland**
Bristol-Myers Squibb GmbH & Co. KGaA
Tel: + 49 89 121 42-0

**Eesti**
Pfizer Luxembourg SARL Eesti filiala
Tel: +372 666 7500

**Ελλάδα**
PFIZER ΕΛΛΑΣ Α.Ε.
Τηλ.: +30 210 67 85 800

**España**
Bristol-Myers Squibb, S.A.
Tel: + 34 91 456 53 00

**France**
Bristol-Myers Squibb SARL
Tél: +33 (0)1 58 83 84 96

**Hrvatska**
Pfizer Croatia d.o.o.
Tel: + 385 1 3908 777

**Ireland**
Bristol-Myers Squibb Pharmaceuticals uc
Tel: + 353 (0)1 483 3625

**Ísland**

**Lietuva**
Pfizer Luxembourg SARL filialas Lietuvoje
Tel. +3705 2514000

**Luxembourg/Luxemburg**
N.V. Bristol-Myers Squibb Belgium S.A.
Tél/Tel: + 32 2 352 76 11

**Magyarország**
Pfizer Kft.
Tel.: + 36 1 488 37 00

**Malta**
V.J. Salomone Pharma Ltd.
Tel: + 356 21 22 01 74

**Nederland**
Bristol-Myers Squibb B.V.
Tel: + 31 (0)30 300 2222

**Norge**
Bristol-Myers Squibb Norway Ltd
Tlf: + 47 67 55 53 50

**Österreich**
Bristol-Myers Squibb GesmbH
Tel: + 43 1 60 14 30

**Polska**
Pfizer Polska Sp. z o.o.
Tel.: +48 22 335 61 00

**Portugal**
Bristol-Myers Squibb Farmacêutica Portuguesa, S.A.
Tel: + 351 21 440 70 00

**România**
Pfizer România S.R.L.
Tel: +40 21 207 28 00

**Slovenija**
Pfizer Luxembourg SARL
Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana
Tel: + 386 (0) 1 52 11 400

**Slovenská republika**
Icepharma hf.  
Sími: +354 540 8000  

**Italia**  
Bristol-Myers Squibb S.r.l.  
Tel: + 39 06 50 39 61  

**Suomi/Finland**  
Oy Bristol-Myers Squibb (Finland) Ab  
Puh/Tel: + 358 9 251 21 230  

**Κύπρος**  
PFIZER ΕΛΛΑΣ Α.Ε. (CYPRUS BRANCH)  
Τηλ: +357 22 817690  

**Sverige**  
Bristol-Myers Squibb AB  
Tel: + 46 8 704 71 00  

**Latvija**  
Pfizer Luxembourg SARL filiāle Latvijā  
Tel: +371 670 35 775  

**United Kingdom**  
Bristol-Myers Squibb Pharmaceuticals Ltd  
Tel: + 44 (0800) 731 1736  

This leaflet was last revised in {MM/YYYY}.  

Detailed information on this medicine is available on the European Medicines Agency web site:  